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Drugs cost lives. 
In an age when the speed of information can often outstrip the 
speed of verification, the COVID-19 pandemic has taught us 
that it is crucial to cut through the noise and focus on facts, a 
lesson that we must heed in order to protect societies from the 
impact of drugs.
Drug use killed almost half a million people in 2019, while drug 
use disorders resulted in 18 million years of healthy life lost, 
mostly due to opioids. Serious and often lethal illnesses are 
more common among drug users, particularly those who inject 
drugs, many of whom are living with HIV and Hepatitis C. 
The illicit drug trade also continues to hold back economic and 
social development, while disproportionately impacting the 
most vulnerable and marginalized, and it constitutes a 
fundamental threat to security and stability in some parts of 
the world.
Despite the proven dangers, drug use persists and, in some 
contexts, proliferates. Over the past year, around 275 million 
people have used drugs, up by 22 per cent from 2010. By 2030, 
demographic factors project the number of people using drugs 
to rise by 11 per cent around the world, and as much as 40 per 
cent in Africa alone.
There is often a substantial disconnect between real risks and 
public perception. In some parts of the world for example, 
cannabis products have almost quadrupled in potency, and yet 
the percentage of adolescents who perceive cannabis as harmful 
has dropped by as much as 40 per cent, despite the evidence 
linking regular use to health problems, particularly in young 
people, and despite the correlation between potency and harm. 
New psychoactive substances also continue to be a challenge, 
as markets witness the introduction of new drugs that are 
unpredictable and poorly understood. Regulatory and legislative 
steps have been successful in stemming the tide globally, but 
in low-income countries the problem is on the rise; between 
2015 and 2019, South and Central America recorded a fivefold 
rise in the amount of new synthetic psychoactive substances 
seized, while seizures in Africa increased from minor to 
substantial amounts. Strong increases were also reported in 
South and Southwest Asia as well as the Near and Middle East. 
Meanwhile, the COVID-19 crisis has pushed more than 100 
million people into extreme poverty, and has greatly exacerbated 
unemployment and inequalities, as the world lost 114 million 
jobs in 2020. In doing, so it has created conditions that leave 
more people susceptible to drug use and to engaging in illicit 
crop cultivation. 
Furthermore, disparities in access to essential controlled 
medicines around the world continue to deny relief to patients 
in severe pain. In 2019, four standard doses of controlled pain 
medication were available every day for every one million 
inhabitants in West and Central Africa, in comparison to 32,000 
doses in North America.
In parallel, drug traffickers have quickly recovered from the 
initial setback caused by lockdown restrictions and are operating 
at pre-pandemic levels once again. Access to drugs has also 
become simpler than ever with online sales, and major drug 
markets on the dark web are now worth some $315 million 
annually. Contactless drug transactions, such as through the 
mail, are also on the rise, a trend possibly accelerated by the 
pandemic.
Communicating facts about drugs and promoting science-based 
interventions is an absolute necessity if we are to reduce 
demand and supply of drugs, while also facilitating access to 
controlled medicines for those in need. It is also the surest path 
to eliminating stigmatization and discrimination and providing 
adequate treatment, as seven in eight people who suffer from 
drug use disorders remain without appropriate care.
At the UN Office on Drugs and Crime we are dedicated to 
pursuing and promoting fact-driven, human rights-based 
approaches to drug control and treatment. 
I am proud to present to you this World Drug Report, which 
embodies our commitment to raising awareness and combating 
misinformation.
It is my hope that this report will inform policymakers, 
practitioners, and the general public on the facts of the world 
drug problem, and provide them with a powerful tool to share 
evidence and information, and in doing so help save and 
preserve lives.
Ghada Waly, Executive Director 
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The designations employed and the presentation of the 
material in the World Drug Report do not imply the 
expression of any opinion whatsoever on the part of the 
Secretariat of the United Nations concerning the legal 
status of any country, territory, city or area, or of its 
authorities, or concerning the delimitation of its frontiers 
or boundaries.
Countries and areas are referred to by the names that 
were in official use at the time the relevant data were 
collected.
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral term “drug use” is used in the 
World Drug Report. The term “misuse” is used only to 
denote the non-medical use of prescription drugs.
All uses of the word “drug” and the term “drug use” in 
the World Drug Report refer to substances controlled 
under the international drug control conventions, and 
their non-medical use.
All analysis contained in the World Drug Report is based 
on the official data submitted by Member States to the 
UNODC through the annual report questionnaire unless 
indicated otherwise.
The data on population used in the World Drug Report 
are taken from: World Population Prospects: The 2019 
Revision (United Nations, Department of Economic and 
Social Affairs, Population Division). 
References to dollars ($) are to United States dollars, 
unless otherwise stated.
References to tons are to metric tons, unless otherwise 
stated. 






Eurojust European Union Agency for Criminal 
Justice Cooperation 
Europol European Union Agency for Law  
Enforcement Cooperation
INCB International Narcotics Control Board
MDMA 3,4-methylenedioxymethamphetamine
NPS new psychoactive substances
RMIT Royal Melbourne Institute of Technology
UNAIDS Joint United Nations Programme  
on HIV/AIDS
UNODC United Nations Office on Drugs  
and Crime







































SPECIAL POINTS OF INTEREST
 » Combat misinformation about the potential impact  
of the increased strength of cannabis.
 » Use fact-based information to raise awareness of the 
potential harm from non-medical use of cannabis.
 » Prioritise public health over private business through  
a comprehensive ban on advertising. 
 » Increase investment in research both into the  
harm cannabis use poses to health and the possible 
medical uses of the drug.
 » Monitor the cannabis markets and the perception  
of risks associated with cannabis use. 
Cannabis is more potent but fewer young people see it as harmful
Rising web-based sales could transform global drug use patterns 
 » Improve government response to drug trafficking  
on the internet by forging public/private partnerships 
with internet service providers, tech companies, 
shipping and mailing companies.
 » Control the drug supply chain on the Internet by 
removing drug adverts and listings and sharing  
information with law enforcement. 
 » Regulate cryptocurrency markets and monitor  
electronic payments to detect suspicious transactions 
and illicit financial flows from drug trafficking.
 » Enhance expert access to the dark web in order to  
















CANNABIS HERB POTENCY 
4X INCREASE
∆9-THC ∆9-THC
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 » Implement an integrated, people-centred and  
human-rights based approach to empowering African 
societies to develop sustainable solutions to drug use.
 » Help African States define and apply innovative  
and cost-effective assessment systems for regular 
monitoring of the drug situation on the continent. 
 » Cultivate strong partnerships between African 
Member States and the United Nations system to 
stem the expected increase in the number of people 










based on growth 

















Number of drug users in Africa is projected to rise by 40 per cent by 2030
SPECIAL POINTS OF INTEREST
FINDINGS POSSIBLE RESPONSES
 » Maintain COVID-19 adaptations to the delivery of 
drug-related services in order to increase accessibility 
and coverage of services. 
 »  Continuously update scientific standards to keep 
abreast of the acceleration of Internet-based services. 
 » Prioritize people who use drugs and with drug use 
disorders for COVID-19 screening and vaccination 
because of their health vulnerability. 
Covid-19 has triggered innovation in  
drug prevention and treatment services 











Mail services for needles 
and syringes and naloxone 
Mobile outreach 
programmes 
Vending machines for sterile 
needle and syringes 




Administration of treatment 
medication without 
face-to-face meetings





SPECIAL POINTS OF INTEREST 
IMPACT OF COVID-19         
FINDINGS POSSIBLE RESPONSES
 » Foster international cooperation for fighting  
the enduring problem of drug trafficking. 
 » Exchange and transfer law enforcement intelligence 
and effective interdiction approaches and best 
practices. 
 » Develop international accountability mechanisms 
and practices for shipping and railway companies, 
postal services, and air cargo.
 » Implement real-time data monitoring systems for 
promptly detecting and addressing drug market 
changes. 
Drug markets quickly recovered after the onset of the pandemic,  
but some trafficking dynamics have been accelerated during Covid-19
Larger shipment size
Increased use of private aircraft
Increased use of waterway routes
Contactless methods to deliver 
drugs to end-consumers
COVID HAS ACCELERATED SOME 
DRUG TRAFFICKING PATTERNS
SPECIAL POINTS OF INTEREST 
IMPACT OF COVID-19                   
FINDINGS POSSIBLE RESPONSES
 » Allocate sufficient funding in national post-covid-19 
budgets for drug prevention and treatment to prevent  
the acceleration of increasing drug use patterns.
 » Prioritize scientific evidence-based prevention  
of drug use in post-pandemic investment. 
 » Pre-empt further increases in the number of people 
who use cannabis, and the harm arising from its 
increasing non-medical use, through cost-effective 
measures such as prevention.
Non-medical use of cannabis and sedatives has increased globally during the pandemic 
NON-MEDICAL USE OF CANNABIS AND 













 » Support parents and young people in vulnerable 
circumstances to face the stresses of the pandemic 
without resorting to negative coping mechanisms. 
 » Alleviate the negative consequences for vulnerable 
and marginalized population groups through post- 
pandemic recovery plans that include housing, food 
supply, economic assistance and health insurance. 
 »  Increase the effectiveness of alternative develop- 
ment interventions to improve the conditions of  
rural households. 
Covid-19 fallout is likely to be felt in drug markets for years to come
POST-COVID ECONOMIC CRISIS 







 p r e d i c t e d
++
food insecurity may intensify
illicit drug cultivation
and production
a protracted economic crisis 
may  accelerate progression 
to drug use disorders
SPECIAL POINTS OF INTEREST 
IMPACT OF COVID-19         
FINDINGS POSSIBLE RESPONSES
THE WORLD DRUG PROBLEM 
COMMON CHALLENGE  
LOCAL DYNAMICS
high level of opioid-related overdoses
 increasing use of methamphetamine
cocaine use  







expanding cocaine market 
increasing use of ATS
opiates use 
non-medical use of tramadol 
increasing cocaine tracking 
heroin in transit spilling over into local heroin use
high prevalence of HIV among
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use of synthetic stimulants
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cking
high prevalence of HIV among
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Amphetamine-type stimulants (ATS) 
HIV among PWID
THE WORLD DRUG PROBLEM  
COMMON CHALLENGE, LOCAL DYNAMICS
While cannabis trafficking and 
use affect all regions worldwide, 
other drug issues pose additional 
threats in different geographical 
locations.
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 > Roughly 200 million people used cannabis  
in 2019 representing 4 per cent of the global 
population. 
 > The figure is highest in North America  
(14.5 per cent) and lowest in Asia (2 per cent).
 > The number of cannabis users has increased 
by nearly 18 per cent over the past decade
 > No data are available on the global illicit 
cultivation of cannabis but qualitative 
information suggests an overall expansion 
between 2010-2019.
 > Between 2009–2019, quantities seized fell  
by 35 per cent, largely because of dramatic 
declines in North America partly linked to 
legalization of non-medical cannabis in some 
jurisdictions.
 > Excluding North American data, global 
seizures were 36 per cent higher in 2019  
than in 2009.
 > Diverse cannabis products have becoming 
more potent yet the number of adolescents 
regarding the drug as harmful is declining 
rapidly, a trend that risks increasing the 
negative impact of cannabis on younger 
generations.
 > An increase in cannabis use has been 








 > An estimated 20 million people used cocaine 
in 2019, corresponding to 0.4 per cent of the 
global population.
 > The prevalence rate of use was the highest  
in Oceania (2.7 per cent), mainly reflecting  
the situation in the sub-region Australia  
and New Zealand, and the lowest in Asia  
(0.07 per cent).
 > Global prevalence rates have remained stable 
over the past decade, while the number of 
people using the drug increased by 22 per 
cent largely owing to population growth.
 > Global manufacture doubled in output 
between 2014 and 2019 to reach an estimated 
1,784 tons, the highest level ever recorded.
 > The quantity seized more than doubled in  
the same period, with the Americas account-
ing for close to 83 per cent of global quantity 
intercepted in 2019.
 > Following an upward trend over the period 
2013–2017, illicit coca cultivation stabilised  
in 2018 and then declined for the first time  
in years by 5 per cent in 2019. 
 > Cocaine manufacture was disrupted  
during the initial stages of the pandemic  
but returned to its typical level shortly 
afterwards.
 > The cocaine trafficking route between South 
America and Europe is evolving, with greater 
competition between traffickers pushing up 
the quality and reducing prices, which is likely 
to continue to widen the potential harm 






 > Around 62 million people used opioids for 
non-medical purposes in 2019, corresponding 
to 1.2 per cent of the global population.
 > North America (3.6 per cent) has the highest 
prevalence, Europe the lowest (0.8 per cent).
 > The number of users worldwide has nearly 
doubled over the past decade, with the 
increase in the last few years mainly driven  
by new estimates in Asia and Africa.
 > Following a decline in the area under illicit 
cultivation of opium poppy from a peak in 
2017, it rebounded in 2020, rising by 24 per 
cent compared with the previous year,  
to reach 295,000 ha.
 > Global opium production has stabilised since 
2018, amounting to 7,430 tons in 2020.
 > Both opium production and opiate seized have 
shown an upward trend over the past two 
decades.
 > Most opiate seizures are made in, or close to, 
the main opium production areas in Asia, 
which accounted for 76 per cent of all opiates 
seized worldwide in 2019.
 > Heroin trafficking was reported in 99 coun-
tries in 2019, a much higher number than 
those reporting trafficking in opium or 
morphine. 
 > Quantities of heroin seized in Europe hit a 
record high in 2019, tripling since 2016, and 
accounting for 27 per cent of the global total.
 > Seizures of “pharmaceutical opioids” hit peaks 
in 2014 and in 2019, almost tripling since the 
previous year to 228 tons.
 > Roughly 50,000 people died from opioid 
overdoses in the United States in 2019, more 
than double the 2010 figure. Fentanyl and  
its analogues now are involved in most of the 
deaths. 
 > North America has seen a spike in opioid 
overdose deaths since the onset of the 
pandemic.
 > As the result of the economic downturn 
triggered by the pandemic, fragile communi-
ties in areas of illicit cultivation of drugs are 
now increasingly vulnerable, especially in 
Afghanistan, where the appeal of illicit crop 
cultivation of opium poppy is likely to rise.
 > Access to pharmaceutical opioids in low- and 
middle-income countries is a tiny fraction of 
the availability in high-income countries.
DRUG-BY-DRUG DEVELOPMENTS IN BRIEF
























 > An estimated 27 million people used 
amphetamine type stimulants in 2019, 
corresponding to 0.5 per cent of the  
global population.
 > The figure was highest in North America (2.3 
per cent) and lowest in Africa (0.4 per cent), 
though the data from Africa was patchy.
 > Nearly 20 million people globally are 
estimated to have used  “ecstasy” in the  
past year.
 > Amphetamine use varies by region. 
Non-medical use of pharmaceutical stimu-
lants and methamphetamine is the most 
prevalent in North America, methamphet-
amine in East and South East Asia and 
amphetamine predominates in Western  
and Central Europe and in the Near and 
Middle East.
 > More than 95 per cent of ATS laboratories 
uncovered between 2015 and 2019 were used 
to manufacture methamphetamine, and the 
drug accounted for 72 per cent of the total 
quantity of ATS seized in the same period.
 > The quantities of ATS seized rose by 64 per 
cent between 2018 and 2019 to record levels, 
capping an almost sixfold increase in the past 
decade while methamphetamine showed a 
tenfold increase over the same period.
 > Ecstasy and amphetamine seizures doubled 
between 2015 and 2019.
 > Roughly 85 per cent of amphetamine 
laboratories dismantled worldwide between 
2015 and 2019 were in Europe, along with 
more than half of ecstasy laboratories.
 > Most methamphetamine was seized in North 
America (49 per cent) and East and South-
East Asia (43 per cent); most amphetamine 
was seized in the Near and Middle East and 
South West Asia (49 per cent) and in Europe 
(26 per cent); and most ecstasy was seized  
in Europe (43 per cent) and North America 
(21 per cent) over the period 2015–2019. 
 > Seizures of precursor chemicals under 
international control used in the manufacture 
of methamphetamine have all but collapsed 
in the past decade, as manufacturers continue 
to change the chemicals they use to bypass 
interdiction.
 > Injecting and use of stimulants is driving HIV 

























 > There are some declines in the use of NPS  
in North America and in Europe, but NPS  
use continues among some marginalized 
population groups. 
 > The use of NPS appears to be rapidly emerg-
ing in some low- and middle-income 
countries.  
 > The harms from NPS use, though may vary 
according to the type of substance, are 
observed/visible more at the individual rather 
than at the population level.
 > The number of NPS found at global level has 
been stabilizing in recent years at slightly 
more than 500 substances (541 in 2019) while 
the actual number of new psychoactive 
substances identified for the first time at 
global level declined from 213 to 71 between 
2013 and 2019 
 > The number of NPS with opioid effects  
(often fentanyl analogues), have been growing 
strongly over the past decade and continued 
growing in 2018 and in 2019, though at a lesser 
pace than before. 
 > Quantities of synthetic NPS seized have 
declined markedly, including of synthetic 
cannabinoids. 
 > National and international drug control 
systems have succeeded in containing the 
spread of NPS in high-income countries  
where different types of legislation have  
been applied. 
 > NPS markets are emerging in countries  
where control systems may be weaker.
 > The limited capacity of forensic, law enforce-
ment and health experts to identify different 
NPS and their use makes it challenging for 
countries to adequately address the threat  
of NPS.

FINDINGS AND CONCLUSIONS 
 &  
POLICY IMPLICATIONS
CANNABIS IS MORE POTENT BUT FEWER  
YOUNG PEOPLE SEE IT AS HARMFUL
Cannabis products have almost quadrupled in strength in the United 
States of America and have doubled in Europe in the last two decades. 
The percentage of Δ9-THC, the main psychoactive component in can-
nabis, rose from about 4 per cent to 16 per cent in the United States 
over the period 1995–2019, and from about 6 per cent to 11 per cent in 
Europe over the period 2002–2019. 
Δ9-THC is responsible for the development of mental health disorders, 
in long-term, heavy users of cannabis yet the percentage of adolescents 
perceiving cannabis as harmful has decreased by as much as 40 per 
cent during the same period. Surveys of schoolchildren and young adults 
in the United States and Europe bear out this finding. Limited evidence 
from other parts of the world suggests a similar pattern.
Such a mismatch between the perception and the reality of the risk 
posed by more potent cannabis could increase the negative impact of 
the drug on young generations. Scientific evidence has demonstrated 
the harm to health caused by regular use of cannabis, particularly in 
young people. Evidence from surveys suggests a link between a low 
perception of risk and higher rates of usage. This is the case not only 
in Europe and the United States, but also in other parts of the world.
Aggressive marketing of cannabis products with a high THC content 
by private firms and promotion through social-media channels; can 
make the problem worse. Products now on sale include cannabis flower, 
pre-rolled joints, vaporizers, concentrates and edibles. The potency of 
those products varies and can be unpredictable – some jurisdictions 
where cannabis use is legalized set no limit on THC content – and may 
be a public health concern.
Combating misinformation on the impact of the use of cannabis prod-
ucts is crucial to enabling individuals, particularly young people, to 
make decisions based on an accurate perception of the risks. 
Awareness-raising and communication efforts that disseminate sci-
entific information without stigmatizing people who use drugs or people 
with drug use disorders can help to avoid misperceptions. Messages 
must be fact-based and a clear distinction must be made among the 
effective medical uses of cannabis products for some ailments, the use 
of cannabis products such as CBD in the so-called wellness industry 
and the consequences of the non-medical use of cannabis. 
A comprehensive ban on advertising, promoting and sponsoring can-
nabis would ensure that public health interests prevail over business 
interests. Such a ban would need to apply across all jurisdictions. The 
measures could work in a way similar to the provisions of the WHO 
Framework Convention on Tobacco Control. 
More investment is needed for research into the harm that the non-med-
ical use of cannabis poses to health and to better define the range of 
health conditions for which cannabis products may be an effective 
treatment. 
Global monitoring of the impact of laws that allow for the medical 
and non-medical use of cannabis is key. This will need to go beyond the 
trends in cannabis use in a single country to assessing the frequency 
and patterns of cannabis consumption, health and socioeconomic con-
sequences and market developments in both the licit and the illicit 
sectors around the world. One important aspect to evaluate is the 
impact of cannabis legalization on the perception of risks associated 
with cannabis use, particularly among young people, beyond the coun-
tries where this legalization is taking place; it would also be critical to 
assess the risk perceived by young people in low-income countries. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
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PERCEPTION AMONG ADOLESCENTS OF  
RISK/HARM OF SMOKING CANNABIS REGULARLY
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RISING SALES OVER THE INTERNET COULD TRANSFORM 
GLOBAL PATTERNS OF DRUG DISTRIBUTION AND USE
Drug markets on the darknet only emerged a decade or so ago, but the 
main ones are now worth at least $315 million in annual sales. Although 
this is a tiny fraction of overall drug sales, the trend is upward, with a 
fourfold increase in annual sales between the beginning of the 2010s 
(2011–mid-2017) and more recent years (mid-2017–2020). The expan-
sion of online drug markets to social media and popular e-commerce 
platforms further suggests that their accessibility is widening. 
While cannabis dominates darknet sales, marketing on the so-called 
clear web often involves NPS and substances used in the manufacture 
of synthetic drugs, including precursor chemicals.
Vendors play a cat-and-mouse game with law enforcement by market-
ing their products as “research chemicals” or advertising “custom 
synthesis”, whereby clients can request substances not included on a 
list of available products. While this is a legitimate practice in the phar-
maceutical industry, it may be misused by traffickers to distribute 
controlled substances.
Rapid technological innovation, combined with the agility and adapt-
ability of those using new platforms to sell drugs and other substances, 
may usher in a globalized market where more drugs become available 
in more locations, especially since traffickers can quickly adapt their 
distribution networks. This in turn will trigger accelerated changes in 
patterns of drug use. 
Increasing the capacity of law enforcement agencies to address drug 
trafficking over the darknet remains a priority, but the increased use of 
the clear web requires innovative solutions and international 
cooperation. 
Public-private partnerships have become crucial in addressing drug 
trafficking on the Internet. The drug supply chain now involves Internet 
service providers, technology companies and shipping and mailing 
companies. Government responses can be effective only if they involve 
those actors. 
Joint responses by Governments and the private sector can involve 
controlling and removing advertisements and listings of illegal drugs 
on the Internet. Such initiatives should facilitate the sharing of pro-
portionate, lawful and necessary information with law enforcement 
agencies, while respecting the highest ethical standards to ensure 
freedom of information and respect for privacy.
Targeting the illicit profits and financial flows that govern drug traffick-
ing requires strong regulation and supervision of cryptocurrency 
markets and monitoring of electronic payments to detect and report 
suspicious transactions. Such approaches are effective only if regula-
tions are uniform and compliance is enforced in all jurisdictions, with 
Governments setting a “level playing field”. This will be even more 
important in the future as the payment for drugs sold online is likely 
to shift from traceable cryptocurrencies to “privacy coins”, which pro-
vide a higher degree of anonymity. 
The globalized drug market that is likely to develop on the Internet will 
require a global response, with innovative, human rights-compliant 
tools for law enforcement agencies to investigate the borderless virtual 
space. To respond to this threat, all States will need to be equipped 
with expert access to the darknet and the investigative capability to 
proactively take down online markets and platforms. 
The transnational nature of online drug markets requires a law enforce-
ment capacity that is agile and can have an impact across borders, 
with joint investigation teams from different countries. Addressing the 
needs of prosecutors and judges to obtain and authorize requests for 
data beyond national borders is key in this context. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
24
Darknets, or overlay networks 
within the Internet that can 
only be accessed with speci	c 
software, con	gurations, or 
authorization, and often use a 
unique customized communica-
tion protocol. Two typical darknet 
types are social networks (usually 
used for 	le hosting with a peer-to-
peer connection), and anonymity 
proxy networks such as Tor via an 
anonymized series of connections.
Content indexed by standard 
web-search engines, accessible 
to anyone using the Internet.
 Infrastructure consisting
of a standardized set of 




Internet  Clear web (surface web)
• social networks 
• public pages 
   /pro	les
• online banking
• social networks 
• restricted pages
   /pro	les
Content not indexed by standard 
web-search engines; content 
can be located and accessed 
by a direct URL or IP address 
but may require a password or 
other security access to get past 
public-website pages; includes 
many very common uses such 
as web mail, online banking, 
private or otherwise restricted 
access content and pro	les.
THE INTERNET: CLEAR WEB, DEEP WEB AND DARK WEB
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NUMBER OF DRUG USERS IN AFRICA  
PROJECTED TO RISE BY 40 PER CENT BY 2030
The number of drug users in Africa is projected to rise in the next 
decade by as much as 40 per cent, simply because of demographic 
changes. Although a rise in people who use drugs is predicted across 
the world, it is likely to be particularly pronounced in Africa because 
the population is younger, and drug use is higher among young people 
than among older people. Moreover, the population of Africa is pro-
jected to grow more quickly than that of other regions.
Globally, the number of people using drugs is projected to rise by 11 
per cent by 2030 because of demographic changes alone. Low-income 
countries account for the lion’s share of this rise. 
These transformations will bring challenges: an increase in the number 
of people who use drugs means more people with drug use disorders 
and therefore more need for the services that cater to them. More 
demand for drugs could lead to organized criminal groups increasing 
their activities, presenting a serious challenge for law enforcement 
agencies in parts of the world where the capacity to address such 
problems is often weaker. Existing challenges affecting Africa, such as 
the use of cannabis, the non-medical use of tramadol and the increased 
use of the continent as a transit area for cocaine and heroin trafficking, 
are likely to be exacerbated by an increased number of people who 
use drugs.
The potential surge in the number of people who use drugs in Africa is 
still avoidable. An effective continental response will involve massive 
investment in health and an expansion of evidence-based prevention 
programmes, particularly those focusing on family skills, life skills in 
school and youth participation at the community level. High-quality 
pharmacological and psychosocial services are also needed. People who 
use drugs need a plan for social reintegration that includes provision 
for further education, vocational skills development and employment 
support. Evidence-based services such as family therapy should be tar-
geted at young people with drug use disorders. Equally, provisions need 
to be made for comprehensive HIV prevention, treatment and care 
among people who use drugs in prisons and closed settings. 
The UNODC Strategic Vision for Africa 2030 can support this conti-
nental response with an integrated, people-centred and human 
rights-based approach, empowering African societies as they develop 
sustainable solutions to drug-related challenges. The strategy focuses 
on prevention to address the drivers of threats related to drugs and 
transnational organized crime, supporting and strengthening societies, 
institutions and at-risk and vulnerable groups. It supports specific and 
effective responses to drug trafficking and drug use, as well as drug-re-
lated HIV prevention, treatment and care. 
The projected increase in drug use and the continued dynamism of drug 
markets demand regular monitoring of the drug situation in Africa. 
Data on drug use and its harm and on supply and market indicators 
remain limited. States need a major continental mobilization to help 
them define and apply innovative and cost-effective monitoring and 
assessment systems. This will allow them to produce and use data on 
drug demand and supply and ensure that national authorities have the 
information they need to detect emerging trends while they can still 
be prevented. Strong partnerships will be key in supporting Africa to 
stop the expected increase in the number of people who use drugs and 
the possible negative impact on health and security. African Member 
States can work closely with United Nations partners, leveraging the 
efficiency provided by the United Nations development system reform, 
to deliver more through joint United Nations programmes.
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INCREASE IN POPULATION AT MOST RISK OF DRUG USE  
IS HIGHEST I  C UNTRIES WITH LOW LEVEL OF INCOME
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IMPACT OF COVID-19  
COVID-19 HAS TRIGGERED INNOVATION  
IN DRUG USE PREVENTION AND TREATMENT SERVICES 
Since the COVID-19 pandemic swept the world, many tasks once con-
ducted face to face have been carried out using Internet-based 
technology, telephones or the postal system. In some countries, rapid 
innovation has transformed what health professionals treating people 
who use drugs can offer.
Despite some disruption to drug treatment services in the first months 
of the pandemic, many countries were quick to introduce telemedicine 
to comply with stay-at-home measures and physical-distancing rules. 
This enabled health-care workers to offer counselling and initial assess-
ments over the telephone. However, in many instances, the closure of 
non-essential health services and movement restrictions brought about 
the sudden and uncoordinated discontinuation of services for people 
with drug use disorders during the initial lockdown periods. 
In addition, prescribing requirements have been simplified and patients 
have been given more flexibility with opioid agonist medication and 
some people suffering from drug use disorders have been allowed to 
take home methadone doses. Other practices include using vending 
machines to dispense opioid agonist medication and postal services to 
distribute sterile needles and syringes. Many of these novel approaches 
will need to be evaluated to better assess their effectiveness. 
Adaptations made as a result of COVID-19 to the delivery of services 
for drug use prevention and the treatment, care and rehabilitation of 
drug use-related disorders and HIV have great potential to increase 
the accessibility and coverage of services if they remain in place after 
the pandemic. The acceleration of Internet-based services creates a 
need for the updating of scientific standards on drug use prevention 
and the treatment, care and rehabilitation of drug use-related disorders 
and HIV. To ensure equal access to Internet-based services, particularly 
among the most marginalized, these standards will need to consider 
the different level of information technology literacy and access across 
the globe. 
Evidence showing the health vulnerability of people who use drugs and 
with drug use disorders, including of those living with infectious dis-
eases and those in prison, point to the need to prioritize these groups 
for COVID-19 screening and vaccination. People who use drugs, both 
in the community and in prison, need to be included in national plans 
for pandemic response. Such plans must ensure the continuity of treat-
ment, care and rehabilitation services for people who use drugs, both 
in the community and in prison. Protecting the human rights of people 
who use drugs and reducing stigma, discrimination and inequality must 
remain key objectives if public health outcomes are to be optimized 
during the current and future pandemics.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
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RESILIENCE OF DRUG MARKETS DURING THE PANDEMIC HAS 
ONCE AGAIN DEMONSTRATED TRAFFICKERS’ ABILITY TO ADAPT 
QUICKLY TO CHANGED ENVIRONMENTS AND CIRCUMSTANCES. 
Drug markets were temporarily disrupted in most parts of the world 
during the first phase of the COVID-19 pandemic, but they have recov-
ered quickly. 
Nevertheless, the pandemic has triggered or accelerated some pre- 
existing trafficking dynamics. These include larger shipment sizes and 
increased use of land and waterway routes, private planes, air cargo 
and postal parcels and contactless methods for delivering drugs to 
consumers, such as mail delivery. 
Fostering international cooperation remains a key objective for fight-
ing the enduring problem of drug trafficking. It is essential that law 
enforcement agencies operating at key border points exchange infor-
mation and transfer knowledge at the regional and international levels 
on effective interdiction approaches and best practices. Together, they 
can define new strategies to improve targeted control of containers 
and cargo shipped along air and maritime routes.
Surveillance and targeting capacity with regard to maritime, land, rail 
and air cargo must be improved substantially, but this can only be 
achieved if intelligence is effectively shared between national author-
ities and the private sector, such as shipping companies and commercial 
airlines. The development of international accountability mechanisms 
and best practices for shipping companies, postal services and railway 
operators with regard to tracking suspicious shipments would greatly 
increase interception capacity. This should go together with strategies 
aimed at addressing changes in trafficking dynamics through reinforced 
screening and the identification of suspicious air cargo on private and 
commercial aircraft.
Continual changes in the routes and tactics employed by traffickers 
require real-time data-monitoring systems that can reinforce border 
management mechanisms and the knowledge of border control offi-
cials. Such systems can guide the priorities of law enforcement agencies 
and help to shape the training and mentoring of officers operating at 
major border points.








































DURING THE COVID-19 PANDEMIC THERE HAS BEEN  
 A CLEAR CHANGE IN THE MODE OF TRANSPORTATION  
OF SMALL-SCALE DRUG SEIZURES
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Most countries have seen an increase in the use of cannabis and 
non-medical use of pharmaceutical drugs such as benzodiazepines 
during the pandemic. In a survey of health professionals in 77 countries, 
a rise in the non-medical use of sedatives was reported in 64 per cent 
of countries and the consumption of cannabis was reported to have 
increased in 42 per cent. 
Changes in patterns of use of other substances were less clear, but 
drugs such as “ecstasy” and cocaine that are typically used in social 
settings were being used less frequently.
North America has seen a spike in opioid overdose deaths since the 
onset of the pandemic. For example, opioid overdose deaths in Canada 
were 58 per cent higher during the quarter April–June 2020 as com-
pared with the same period in 2019. Measures related to COVID-19 are 
known to have increased economic deprivation and feelings of social 
isolation, factors that can contribute to increased drug use.
Sufficient funding for drug use prevention and treatment responses 
needs to be allocated in national post-COVID-19 budgets to avoid 
an acceleration of the increase in the use of certain drugs observed 
during the pandemic. Annual health budgets need to include a dedi-
cated percentage for drug use prevention and treatment and 
HIV-related issues. 
This will allow the coverage of services to be expanded and the quality 
to be improved, ensuring that people with drug use disorders do not 
resort to the use of more harmful substances or methods of adminis-
tration. Negative outcomes such as drug-related deaths will therefore 
be reduced. 
Prevention is a cost-effective measure to pre-empt further increases 
in the number of people who use cannabis and the harm arising from 
its increasing non-medical use. Post-pandemic investment needs to 
prioritize scientific evidence-based prevention of drug use and other 
risky behaviours, with a special focus on the development of life skills 
in children and young people, parenting and family skills, and mental 
health services.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
NON-MEDICAL USE OF CANNABIS AND SEDATIVES  
HAS INCREASED DURING THE PANDEMIC
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The pandemic has brought increasing economic hardship along with 
radical shifts in technology and dramatic alterations in social habits 
that are likely to affect drug patterns in the long run. 
Fragile communities in opium poppy and coca bush cultivation areas 
have become increasingly vulnerable as the pandemic has affected 
their livelihoods. In Afghanistan, for example, the pandemic came after 
a drought in 2018 and floods in 2019, meaning that many farmers were 
already struggling to cope. The economic crisis brought on by the pan-
demic will only increase the appeal of illicit crop cultivation. Rising 
unemployment may mean that more people are willing to work as daily 
labourers for opium gum and coca leaf harvesting, while drug traffick-
ers may also find recruitment easier in a time of hardship.
Meanwhile, inequality, poverty and mental health conditions are on 
the rise across the world, and these are known factors that push people 
into drug use and cause negative health consequences and a rise in 
drug use disorders. Changes already observed in drug use patterns, 
including increases in the use of cannabis and the non-medical use of 
pharmaceutical sedatives, are likely to accelerate the expansion of the 
market for these substances.
This is all likely to be fuelled by innovation in the retail distribution of 
drugs, with street dealing becoming less prevalent as contactless meth-
ods such as online purchasing and delivery by mail – and even drones 
– become more common.
Prevention through support to parents and young people in vul-
nerable circumstances, so that they can better face the stresses of the 
pandemic without resorting to negative coping mechanisms, will be 
particularly needed in the recovery phase. Effective practices include 
the provision of training in family skills, shelter for people suffering 
domestic abuse and mental health services. 
Post-pandemic recovery plans are opportunities to alleviate the neg-
ative consequences of the pandemic for vulnerable and marginalized 
groups. Communities of people who use drugs and communities 
engaged – or at risk of engaging – in illicit drug cultivation and pro-
duction should be included in programmes involving housing, food 
supply, economic assistance and health insurance. 
Development assistance to rural villages engaged in illicit drug culti-
vation is crucial to prevent increased engagement in production and 
trafficking by people who have lost employment because of the pan-
demic. Long-term investment in sustainable alternative development 
interventions can improve the conditions of households in rural areas. 
If implemented early in the recovery phase, these measures could steer 
households away from illicit activities and prevent the migration of 
labour to illicit drug economies, helping to secure the progress made 
in recent years. 
Alternative development interventions can help communities to boost 
their skills, improve their infrastructure and move beyond basic live-
lihood development levels in ways that do not damage the environment. 
Moreover, involving the private sector can dramatically expand the 
profitability of products or services. Measuring the impact of these 
alternative development interventions will be important for strength-
ening the evidence base and further increasing the effectiveness of 
such projects.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
COVID-19 FALLOUT LIKELY TO BE FELT  
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The number of NPS emerging on the global market fell from 163 in 2013 
to 71 in 2019. This reflects trends in subregions such as North America 
and Western and Central Europe, where the main markets for NPS first 
emerged a decade ago.
The figures suggest that national and international control systems 
have succeeded in limiting the spread of NPS in high-income countries. 
Some high-income countries have adopted generic legislation covering 
possible future variants of controlled substances; others have applied 
analogue legislation more strictly than in the past, allowing the courts 
to determine whether substances have structures and effects similar 
to others already under national control.
However, the NPS problem has now spread to poorer regions, where 
control systems may be weaker. For example, seizures of synthetic NPS 
in Africa rose from less than 1 kg in 2015 to 828 kg in 2019. There was 
a similar trend in Central and South America, with seizures rising from 
60 kg to 641 kg over the same period.
There is much to learn from the positive trend of NPS containment. 
Countries and regions that have more recently been exposed to the 
challenge of NPS can benefit greatly from increased international 
cooperation and the transfer of best practices from the countries 
that have managed to contain the problem through legislative, law 
enforcement and forensic efforts. 
Responses that have helped to contain the supply of NPS and reduce 
negative health consequences can be expanded to lower-income coun-
tries, some of which are increasingly vulnerable to the emergence of 
NPS. Those responses include early warning mechanisms that ensure 
a continuum of evidence-based measures from early detection to early 
action, post-seizure inquiries, including the formation of joint inves-
tigation teams, and training of emergency health workers on how to 
address cases of acute NPS intoxication. The expansion of services for 
people who use drugs and people with drug use disorders to people 
who use NPS can also help addressing the harm posed by those 
substances.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
NUMBER OF NPS EMERGING IN HIGH-INCOME  
COUNTRIES IS FALLING, BUT AVAILABILITY MAY  
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The cocaine trafficking route between South America and Europe is 
the second biggest in the world, and it is evolving. Supply chains once 
dominated by a few organized criminal groups are changing, with many 
more groups involved. 
Much of the cocaine in Europe used to be imported through well-es-
tablished channels, notably by Italian organized criminal groups and 
through alliances between Colombian and Spanish groups. Now, how-
ever, organizations originating in the Balkans are increasingly involved 
in trafficking and supply, and some are now cutting out intermediaries 
and sourcing cocaine directly from the production areas in the Andean 
region.
The increased competition and efficiency of supply mean that cocaine 
is becoming more available and the quality is rising. The purity of 
cocaine available in Europe has increased by 40 per cent in the past 
decade, meaning that high-quality cocaine has, in effect, become 
cheaper per pure unit.
Easier access to high-quality cocaine is likely to increase the overall 
number of people using cocaine and encourage those people who cur-
rently use cocaine to use more. This will continue to increase the 
potential harm caused by the drug.
Preventing increases in the supply of cocaine from translating into 
more people using the substance and more associated harm needs 
solid investment in drug use prevention and treatment. This invest-
ment should focus on targeting people who could possibly initiate use 
of cocaine and on research to develop pharmacological responses. A 
real-time monitoring system of both supply and demand and the illicit 
financial flows generated by the cocaine market is also needed to 
better understand how to target traffickers’ profits. 
Preventing the threat of a further increase in the cocaine supply to 
Europe requires the boosting of international cooperation between 
the Americas and Europe and the transfer of best law enforcement 
practices in terms of targeting loose criminal networks and new com-
munication tools. Such cooperation needs to include not only law 
enforcement but also prosecutors, and should also involve the promo-
tion of joint investigation teams through Eurojust and Europol.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
COCAINE SUPPLY CHAINS TO EUROPE ARE DIVERSIFYING,  
PUSHING PRICES DOWN AND QUALITY UP, THREATENING  
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Afghanistan reported a 37 per cent increase in the amount of land used 
for illicit cultivation of opium poppy during 2020 compared with the 
previous year. It was the third highest figure ever recorded in the coun-
try and accounted for 85 per cent of the global total of opium production 
in 2020. The increase follows a trend that has seen the global area 
under opium poppy cultivation rise over the past two decades, partic-
ularly after 2009.
Afghanistan is also now becoming a major source for methamphet-
amine in the region. In neighbouring the Islamic Republic of Iran, the 
proportion of Afghan-origin methamphetamine seized increased from 
less than 10 per cent in 2015 to more than 90 per cent in 2019. Seizures 
in Afghanistan increased almost sevenfold in 2019 as compared with 
a year earlier. This came even as air strikes in Taliban-held border regions 
wiped out dozens of methamphetamine laboratories in a single day in 
2019.
The expansion of methamphetamine manufacture adds complexity to 
the illicit drug economy of Afghanistan and increases the threat to 
countries in the region and beyond. Political instability could further 
increase the vulnerability of local communities to both the production 
of opium and the manufacture of methamphetamine.
The health consequences of the surge in methamphetamine manufac-
ture in Afghanistan are already beginning to affect the country. Young 
people are now exposed not only to the largest supply of opiates in the 
world in one of the largest illicit drug economies, but also to an increas-
ingly diversified market of synthetic drugs. Surveys show a relatively 
high proportion of young people reporting recent methamphetamine 
use. 
Afghanistan is a prime example of how politics, security and narcotics 
interlink. With politics and security being discussed during the current 
peace negotiations, the illicit economy as an important wealth creator 
is not to be overlooked. In the meantime, strengthening alternative 
livelihoods will help to reduce opium cultivation, build community 
resilience in uncertain times and stem outward migration. Beyond this, 
regional cooperation is crucial among the countries immediately 
affected by the expansion of both opiates and synthetic drugs. Strength-
ening international cooperation with Afghanistan is today more 
important than ever, given that international troops will soon be leav-
ing the country. Identifying targets, supporting regional counter-narcotics 
operations and proposing regional action plans are now a priority 
for setting responses to the trafficking of drugs originating in 
Afghanistan. 
The drug problem faced by Afghanistan has regional and global roots 
and ramifications. At the national level, Afghanistan needs support 
to provide sustainable and viable alternative livelihoods to rural com-
munities, to strengthen interdiction through poppy eradication and to 
promote counter-narcotic campaigns. The country also needs help to 
increase capacity to disrupt manufacturing and trafficking networks, 
as well as to improve governance and security. It faces the task of 
addressing negative health consequences related to the drug use prob-
lem that is now growing in complexity with the increased use of 
synthetic drugs, particularly among young people.
At the regional level, countries need support in the use of advanced 
investigative techniques in controlled delivery operations, backtracking 
investigations and money-laundering and financial investigations aimed 
at dismantling criminal organizations involved in trafficking drugs and 
their precursors in the region. Law enforcement education and training 
institutions need to operate under international standards in the iden-
tification and analysis of forensic evidence to track the movement of 
illicit drugs and their precursor chemicals in West and Central Asia. It 
would be particularly effective to provide support in addressing the 
diversion of precursor chemicals required in heroin and methamphet-
amine manufacture. 
Regional and subregional law enforcement cooperation platforms, 
including the Central Asian Regional Information and Coordination 
Centre, the Triangular Initiative and its Joint Planning Cell, and the Afghanistan– 
Kyrgyzstan–Tajikistan Initiative, need to be strengthened.
Developments in Afghanistan call for improved analysis of the impact 
of the illicit drug economy and more comprehensive monitoring of the 
drug market, particularly methamphetamine and the chemicals used 
in its manufacture. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
DEEPENING DRUG PROBLEM IN AFGHANISTAN  
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While the amount of methamphetamine seized increased threefold 
between 2011 and 2019, seizures of its internationally controlled pre-
cursors declined by 99 per cent over the same period. The internationally 
controlled precursor chemicals seized in 2011 would have been enough 
to manufacture 700 tons of the drug, seven times the amount of meth-
amphetamine intercepted that year. By 2019, the amount of precursor 
chemicals seized had fallen to an equivalent of 10 tons of methamphet-
amine, whereas a much higher quantity of the drug, 325 tons, was seized.
This dynamic is down to the agility of traffickers in changing the chem-
icals they use, to bypass interdiction. Criminal groups in Afghanistan 
are known to use the Ephedra plant, which is not internationally con-
trolled, to produce the precursor ephedrine while in North America 
and Western Europe they use non-controlled chemicals to manufacture 
the precursor P-2-P, which is then used to make methamphetamine.
The capacity, know-how and versatility of traffickers in swapping the 
chemicals and tweaking their processes is challenging the capacity of 
Member States to control precursors. The low proportion of precursors 
intercepted could also be caused by law enforcement agencies placing 
a higher priority on the seizure of the end drug product than on the 
seizure of its components.
The partnership between Governments and the private sector has 
become essential in the control of precursors of synthetic drugs, includ-
ing methamphetamine. It helps to identify the possible diversion of 
non-controlled precursors from the licit supply chain. Regular moni-
toring by national authorities, together with the private sector, can 
allow law enforcement to develop the same agility as traffickers 
and to quickly change targets in their precursor control strategy, in 
particular towards non-controlled chemicals. Forensic laboratories with 
the capacity to conduct confirmatory testing on suspected drugs 
and chemicals can also generate important information about meth-
amphetamine, including its chirality and purity, that would allow the 
synthesis routes and the origin of precursor chemicals to be traced. 
The establishment and strengthening of networks of central author-
ities that regulate precursor chemicals based on source, transit and 
destination countries can facilitate information-sharing and initiate 
joint backtracking investigations. These networks can also raise aware-
ness of non-controlled chemicals used in the manufacture of ATS.
Mechanisms that support front-line officers at border checkpoints 
in areas with high trafficking levels can also enhance transnational 
capacity to disrupt flows of controlled and non-controlled chemicals 
in manufacturing areas.
Finally, there is a need to improve the regular monitoring of metham-
phetamine consumption with cost-effective methods such as the 
analysis of wastewater. This type of analysis can also help to identify 
potential clandestine manufacture at the local level.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
METHAMPHETAMINE SEIZURES HAVE ROCKETED  
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The two pharmaceutical opioids most commonly used to treat people 
with opioid use disorders, methadone and buprenorphine, have become 
increasingly accessible over the past two decades. The amount avail-
able for medical use has increased sixfold since 1999, from 557 million 
daily doses in that year to 3,317 million by 2019. This is a positive sign 
that science-based pharmacological treatment is more available now 
than in the past.
However, as with other pharmaceutical opioids, there are large differ-
ences across countries and regions. The availability of these substances 
is generally high in North America, Western and Central Europe and 
in the most-developed parts of Oceania. Many countries in Africa and 
Asia, however, reported either limited availability or no availability of 
either. This results in a varying coverage of opioid agonist treatment 
for drug use disorders.
The availability of the substances for medical purposes can reflect fac-
tors including a country’s income level, the use of such substances for 
analgesic purposes or the number of people with opioid use disorders. 
It can also be affected by policies relating to opioid agonist 
treatment. 
The encouraging trend of increased availability of methadone and 
buprenorphine provides an opportunity for accelerating science-based 
treatment of drug use disorders and making opioid agonist treatment 
more widely available. Special efforts should be made in countries where 
availability remains low, while continuing efforts to prevent the diver-
sion of such substances to illegal markets. Drug treatment should be 
available to all in need, including people with drug use disorders in 
prisons and other closed settings. Approaches adopted during the 
COVID-19 pandemic have shown that access to opioid agonist therapy 
can be maintained even in challenging situations through low-thresh-
old services and the scale-up of take-home therapy.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
PHARMACEUTICAL DRUGS USED TO TREAT OPIOID  
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In 2019, medical professionals in West and Central Africa had access 
to 4 standard doses of controlled pain medication every day per 1 mil-
lion inhabitants. In North America, the figure was about 32,000 doses. 
Patients with acute or chronic pain from serious illnesses such as cancer 
endure unnecessary suffering on a large scale.
The shortages in supply were not limited to Africa. Parts of Asia, Oce-
ania, Central and South America and the Caribbean also reported 
availability that was less than 1 per cent of that of North America.
Overall, the availability of pharmaceutical opioids for each person in 
low- and middle-income countries was less than 1 per cent of that in 
high-income countries in 2019. This is despite 84 per cent of the world’s 
population living in low and middle income countries.
Following the basic tenets of the drug conventions, countries and the 
global community need to strike a better balance in providing access 
to controlled medications to manage pain while avoiding the devel-
opment of a market for the non-medical use of such medications. 
Countries need to address the barriers to equitable access to medi-
cations for pain management and palliative care by reviewing policies, 
addressing challenges in the supply chain, supporting health workers 
and raising awareness among the general public to increase access to 
controlled medicines while preventing diversion and non-medical use.
During the pandemic, accessibility to controlled medications to manage 
pain has been particularly critical to support patients who contracted 
the virus and those who could not access proper care in hospitals 
because of the virus. INCB, UNODC and WHO have called upon Gov-
ernments to ensure that the procurement and supply of controlled 
medicines during the pandemic meets the needs of patients, both those 
who have COVID-19 and those who require internationally controlled 
medicines for other conditions.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
PATIENTS IN SEVERE PAIN IN POORER COUNTRIES  
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Roughly 275 million people globally have used drugs in the past year, 
up from 226 million in 2010. This 22 per cent increase was partly due 
to a 10 per cent rise in the global population. 
Health-care systems are facing an increasingly tough task, with esti-
mates suggesting that about 36 million people were suffering from 
drug use disorders in 2019, up from an earlier estimate of 27 million in 
2010. This represents a rise from 0.6 to 0.7 per cent of the global 
population. 
Although the number of people with drug use disorders has increased, 
the availability of treatment interventions has remained low. Just one 
in eight of those suffering from a drug use disorder received profes-
sional help in 2019. Shortages in these services were felt most of all in 
poorer countries. This is despite overwhelming evidence that the cost 
of treating drug use disorders is much lower than the cost of untreated 
drug dependence.
The rise in people using drugs and suffering drug use disorders has 
gone together with the arrival of hundreds of synthetic drugs on the 
market, and with a dramatic expansion of the non-medical use of opi-
oids. Moreover, some drugs are more potent than they were a decade 
ago. All of this increases the risk to individual users and adds to the 
burden of health-care systems.
Prevention remains the best first-line approach to reducing drug use 
and drug use disorders. The most effective approaches are those that 
contribute to the positive engagement of young people with their fam-
ilies, schools and communities, creating all-inclusive and safe 
neighbourhoods. 
Communities and civil society organizations — including organiza-
tions and networks of people who use drugs, people in recovery and 
other people affected by drugs—can greatly support prevention and 
treatment efforts. They should be included, supported and empowered 
in all aspects of the design, implementation, monitoring and evaluation 
of service delivery.
The increased number of people with drug use disorders globally calls 
for the scaling up of evidence-based interventions that take a multi-
factorial approach. Such interventions should be integrated within the 
overall health-care delivery system and should address the needs of 
those in vulnerable circumstances, including women, children and ado-
lescents and people in contact with the criminal justice system. 
Protecting and promoting the human rights of people who use 
drugs by treating them with dignity, removing stigma and providing 
equal access to health and social services need to be the underlying 
principles of all interventions related to drug use prevention and 
treatment. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
NUMBER OF PEOPLE USING DRUGS HAS RISEN  
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THE NUMBER OF PEOPLE WITH DRUG USE DISORDERS  
WAS IN 2019 33 PER CENT HIGHER THAN IN 2010     
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The amounts of fentanyl and its analogues seized globally have risen 
rapidly in recent years, and by more than 60 per cent in 2019 compared 
with a year earlier. Overall, these amounts have risen more than twenty-
fold since 2015. The largest quantities were seized in North America.
Elsewhere in the world, other pharmaceutical opioids (codeine and 
tramadol) predominate. Over the period 2015–2019, the largest quan-
tities of tramadol seized were reported in West and Central Africa; they 
accounted for 86 per cent of the global total. Codeine was intercepted 
in large quantities in Asia, often in the form of diverted cough syrups.
In terms of weight seized, other pharmaceutical opioids far outweigh 
fentanyls. However, when expressed in terms of standard daily doses, 
fentanyl accounted for 63 per cent of the pharmaceutical opioids seized 
in 2019. This figure rises to 83 per cent when all the different fentanyl 
mixtures and analogues are included. 
The seizure pattern of pharmaceutical opioids reflects the different 
illegal markets that feed the non-medical use of pharmaceutical opi-
oids in different regions. The impact of these illegal markets is clear in 
the harm that these substances pose to health. 
Large parts of the illegal markets that feed the non-medical use 
of pharmaceutical opioids are supplied by illegally manufactured 
opioids; reducing these illegal markets requires increased international 
cooperation and law enforcement capacity to dismantle transnational 
drug trafficking groups. In North America, where fentanyls are not gen-
erally diverted from the legal medical market and people often consume 
them inadvertently as a cutting agent of other drugs, attempts to reduce 
the illegal market need to concentrate on dismantling criminal groups 
and stopping illegal manufacturing, particularly through precursor 
control. 
The situation in West, Central and North Africa is more complex. While 
the illegal market for tramadol remains supplied by illegal manufactur-
ing, there is a specific demand related to the non-medical use of 
tramadol. The distinction between the illegal and legal markets for 
medicines is blurred, and there is a large informal market for medicines. 
This environment is also characterized by limited access to essential 
medicines. In this context, law enforcement actions and international 
cooperation remain essential to dismantle relevant criminal groups, 
but they are not sufficient. More needs to be done to determine the 
right balance between providing access to essential medicines and 
avoiding non-medical use. Prevention campaigns need to be designed 
to make people more aware of the benefits of using opioids such as 
tramadol for medical use, and the harm they pose when they are used 
for non-medical purposes. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
FENTANYLS REMAIN THE PHARMACEUTICAL OPIOIDS  
MOST SEIZED IN TERMS OF DOSES, WITH NORTH AMERICA  
DOMINATING THESE SEIZURES
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FENTANYLS REMAIN THE PHARMACEUTICAL OPIOIDS  
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THE SHARP INCREASE IN THE SEIZURES OF FENTANYL  IN NORTH AMERICA  
HAS LEAD GLOBAL SEIZURES OF PHARMACEUTICAL OPIOIDS  
TO BE DOMINATED BY FENTANYL  IN TERMS OF STANDARD DOSES (2019).    
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Global cocaine manufacture doubled in output between 2014 and 2019 
to reach an estimated 1,784 tons in 2019, the highest level ever. Over 
the same period, seizures of cocaine more than doubled. Meanwhile, 
wastewater analysis showed a marked increase in the amounts of 
cocaine consumed per capita in Europe, one of the two main global 
markets. This all points to a surge all along the cocaine supply chain. 
However, the rate of increase in manufacture has slowed. While the 
year-on-year increase in manufacture in 2016 stood at 37 per cent, it 
was just 3.5 per cent in 2019. 
Moreover, the area under coca bush cultivation declined globally by 5 
per cent in 2019, largely driven by the first significant fall in cultivation 
in six years in Colombia. Despite that, the country is still by far the 
largest source of cocaine globally. The area under cultivation remained 
stable in Peru and increased in the Plurinational State of Bolivia. 
The slowing rate of growth in cultivation had suggested that subse-
quent years would see cocaine manufacture decline. However, the 
COVID-19 pandemic and the resulting socioeconomic fallout may 
increase the vulnerabilities of farmers and create incentives to con-
tinue producing coca leaf.
International assistance for farmers in the coca bush-growing areas 
of the Andean region remains a fundamental pillar in reducing illicit 
cultivation and production in those areas. The strategies that have 
proved to be effective include providing crops and other alternative 
livelihoods that grant food security, and agroforestry solutions that 
open up export markets for sustainable farming and reduce conflict 
levels among coca farmers. 
Large-scale cocaine smuggling out of the Andean countries calls for 
strengthened international cooperation by law enforcement agen-
cies, particularly on land and sea routes for trafficking established in 
response to restrictions to air travel after the COVID-19 outbreak. An 
improvement in container control could be helpful. The Parana-Para-
guay waterway system, for example, needs increased controls at the 
ports connecting several countries to the Atlantic, a route that has been 
rapidly growing in importance. New strategies are needed to address 
the high number of clandestine and domestic ports in the area that are 
increasingly used for alternative trafficking routes. 
The increased use of light aircraft to transport cocaine across South 
America during the COVID-19 pandemic calls for the control of general 
aviation to be strengthened. Technical assistance is particularly effec-
tive in areas such as regulation of pilot licensing and recording of 
transactions involving aircraft parts and aviation fuel. 
Further assistance is required at the forensic level, particularly with 
regard to building laboratory capacity for chemical footprint analysis 
that can ultimately support both domestic and international criminal 
investigations into cocaine trafficking.
Strategies that promote alternative livelihoods to coca bush cultivation 
and coca production must also involve strengthening institutions and 
improving access to the services they provide.
The timely monitoring of coca bush cultivation and cocaine manufac-
ture and trafficking, including related illicit financial flows, remains a 
priority. Along with this, innovative tools and geospatial analysis must 
be used to enhance understanding of the drivers of the coca economy 
and its links with the legal economy in areas along the supply chain. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
GLOBAL AREA UNDER COCA CULTIVATION DECLINES  

































































































Coca bush cul�va�on: Colombia
Coca bush cul�va�on: Peru
Coca bush cul�va�on: Plurina�onal State of Bolivia
Global cocaine manufacture: old conversion ra�o
Global cocaine manufacture: new conversion ra�o
AFTER REACHING A RECORD HIGH IN THE GLOBAL AREA UNDER  
COCA CULTIVATION, LAST ESTIMATE SHOWS A 5 PER CENT DECLINE,  
BUT COCAINE MANUFACTURING IS STILL ON A RISE   
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The methamphetamine market is still expanding in South-East Asia 
and North America, with manufacture moving to geographical areas 
in Myanmar where there is instability and to areas in Mexico where 
there is a strong presence of organized criminal groups.
In the period 2015–2019, more than 90 per cent of the methamphet-
amine seized globally was seized in South-East Asia and North America. 
In North America, seizures increased eightfold, to 153 tons, between 
2009 and 2019. In the same period, there was an elevenfold increase 
in seizures in South-East Asia, to 141 tons. 
The growth of methamphetamine trafficking in North America has 
come at the same time as so-called product innovations that have seen 
the drug take a variety of forms: powder, crystals, solutions and tablets 
that resemble MDMA or falsified pharmaceuticals. Manufacturers in 
North America are also increasingly mixing fentanyls with other drugs, 
contributing to a sharp rise in methamphetamine-related deaths in 
recent years.
In South-East Asia, falling prices of methamphetamine products com-
bined with rising seizures suggests that supply may have outstripped 
demand in the subregion. Organized criminal groups are taking advan-
tage of loose controls over precursor chemicals and sometimes slow 
cooperation across borders. This has brought profound changes to the 
illicit drug markets in South-East Asia and the Pacific. 
Manufacture of the drug has been consolidated in the Golden Triangle 
region of Myanmar, where a decrease in the opium market has been 
observed together with increased manufacture of and trafficking in 
methamphetamine. Security problems and limited access to these 
areas are posing significant challenges. 
In South-East Asia and Mexico, methamphetamine manufacture is con-
nected with violence and insecurity. However, many aspects of the 
institutional and financial mechanisms of this connection remain largely 
unexplored. 
In South-East Asia, providing support to countries surrounding Myan-
mar is crucial given the current volatile situation. It is also important 
to strengthen capacity in neighbouring countries to stop flows of chem-
icals into areas where drugs are produced and manufactured. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
SECURITY GAPS IN AREAS WHERE METHAMPHETAMINE  
IS MANUFACTURED ARE LIKELY DRIVING MARKET 






























































Almost 50,000 people died from overdose deaths attributed to opioids 
in the United States in 2019, more than double the 2010 figure. By 
comparison, in the European Union, the figure for all drug-related 
overdoses (mostly relating to opioid use) stood at 8,300 in 2018, despite 
the larger population.
However, the opioid crisis in North America is evolving. The number 
of deaths attributed to heroin and the non-medical use of pharmaceu-
tical opioids such as oxycodone or hydrocodone has been declining 
over the past five years.
The crisis is now driven mainly by overdose deaths attributed to syn-
thetic opioids such as fentanyl and its analogues. Among the reasons 
for the large number of overdose deaths attributed to fentanyls is that 
the lethal doses of them are often small when compared with other 
opioids. Fentanyl is up to 100 times more potent than morphine. 
The impact of fentanyl is illustrated even further by the fact that more 
than half of the deaths attributed to heroin also involve fentanyls. Syn-
thetic opioids also contribute significantly to the increased number of 
overdose deaths attributed to cocaine and other psychostimulants, 
such as methamphetamine.
To help prevent overdose deaths in North America, it is vital that those 
who are opioid dependent, including those in prison or recently released 
from prison, have access to proper treatment and services. Access to 
methadone and buprenorphine needs to be ensured; increasing the 
availability of take-home naloxone can save many lives. Furthermore, 
scaling up the training of people likely to witness an overdose – includ-
ing peers, family members, first responders and the police – and 
equipping them with naloxone has been shown to be effective. Achiev-
ing this kind of coverage will involve tackling barriers that include cost 
and stigma.
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
OVERDOSES INVOLVING FENTANYLS CONTINUE TO  

















































Deaths involving pharmaceu�cal opioids and other
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Deaths involving heroin and synthe�c opioids (fentanyls)
Deaths involving heroin without other synthe�c opioids
IN THE UNITED STATES, NUMBER OF OVERDOSE DEATHS  
ATTRIBUTED TO HEROIN AND PHARMACEUTICAL OPIOIDS  ALONE  
ARE DECREASING BUT THOSE ATTRIBUTED TO THE  SAME SUBSTANCES  
MIXED WITH FENTANYLS  ARE INCREASING
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The burden of disease caused by drug use continues to increase in 
terms of both premature deaths and the number of healthy years of 
life lost owing to disability. The greatest harm from drugs is associated 
with the use of opioids, in particular, with users acquiring HIV or hepa- 
titis C through unsafe injecting practices. 
In 2019, 18 million years of healthy life were lost owing to drug use 
disorders; opioid use accounted for 70 per cent of the total. 
Deaths related to drug use disorders have nearly doubled over the past 
decade, far outstripping any increase in the number of users, suggest-
ing that drug use has become more harmful. In 2019, half a million 
deaths were attributed to drug use. More than half of the deaths were 
due to liver cancer, cirrhosis and other chronic liver diseases resulting 
from hepatitis C, but the increase reflects, in part, the rise in overdose 
deaths attributed to use of opioids such as fentanyls. 
The situation is exacerbated by the continued low availability of evi-
dence-based interventions such as opioid agonist treatment, naloxone 
for opioid overdose management, and prevention and treatment of 
hepatitis C. This is especially the case in poorer countries.
More positively, the past decade has seen a decline in deaths attributed 
to HIV and AIDS among people who use drugs.
Prevention strategies addressing opioid use, overdose deaths and health 
issues that may arise from unsafe injecting practices are essential for 
reducing the burden of disease. Partnerships between first responders, 
public health institutions and public safety authorities can help advance 
prevention efforts. Such efforts can increase public awareness, share 
relevant data to identify at-risk individuals and communities and facil-
itate referrals to treatment and social services.
Reducing the health burden of opioids requires a significant scale-up 
of evidence-based interventions to deal with opioid use disorders, 
especially opioid agonist treatment and prevention of overdose and 
management of overdose cases. It also requires scaling up interventions 
for preventing blood-borne infections and widening the availability of 
hepatitis C treatments for people who use drugs. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
OPIOID USE CONTINUES TO ACCOUNT FOR THE  
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There were more than 11 million people who inject drugs globally in 
2019, of whom 1.4 million are living with HIV and 5.6 million with hep-
atitis C. Almost 1.2 million people live with both. Their primary risk of 
disease comes from sharing contaminated injecting equipment. 
There has been a decline in the number of years lost to the virus in 
terms of premature deaths and disability related to drug use. However, 
people who inject or use drugs are 29 times more likely to acquire HIV 
than the general population. They accounted for 1 in 10 new infections 
in 2019, according to UNAIDS estimates. In recent years, there have 
been localized outbreaks of HIV in countries across Europe and North 
America.
Reducing the negative health impact of drug use requires the full imple-
mentation of a comprehensive package of HIV and hepatitis services. 
This includes the provision of needle-syringe programmes and opioid 
agonist therapy, the supply of naloxone and the treatment of hepatitis 
C. All this will have to be done on a scale that can be easily, voluntarily 
and confidentially accessed by all people who use drugs, including 
within prisons and other closed settings.
Targeted advocacy among health-care providers and law enforcement 
can help to reduce the stigma and discrimination felt by people who 
use drugs. Moreover, gender-specific HIV- and hepatitis C-related ser-
vices should be provided for women who use drugs. 
FINDINGS AND CONCLUSIONS POLICY IMPLICATIONS
BURDEN OF DISEASE REMAINS HIGH  
AMONG PEOPLE WHO INJECT DRUGS
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MORE THAN 11 MILLION PEOPLE INJECT DRUGS 
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eTABLE 1 Annual prevalence of the use of cannabis, opioids and opiates, by region and globally, 2019
Region  
or subregion 
Cannabis Opioids  (opiates and prescription opioids) Opiates













Africa 46,950 28,150 64,080 6.41 3.85 8.75 9,050 6,360 12,140 1.24 0.87 1.66 3,580 1,430 7,910 0.49 0.20 1.08
East Africa - - - - - - - - - - - - - - - - - -
North Africa 7,850 6,900 9,170 5.26 4.63 6.15 1,580 1,060 2,100 1.06 0.71 1.41 1,580 1,060 2,100 1.06 0.71 1.41
Southern Africa - - - - - - - - - - - - - - - - - -
West and  
Central Africa
26,790 14,610 30,360 9.40 5.12 10.65 - - - - - - 520 140 980 0.18 0.05 0.34
Americas 59,130 57,510 62,220 8.77 8.53 9.23 12,580 11,310 13,730 1.86 1.68 2.04 2,550 1,850 3,270 0.38 0.27 0.49
Caribbean 970 500 2,650 3.41 1.77 9.35 - - - - - - - - - - - -
Central America 1,000 340 1,750 3.12 1.08 5.48 - - - - - - - - - - - -
North America 47,120 46,950 47,290 14.53 14.47 14.58 11,790 10,690 12,630 3.63 3.30 3.89 2,280 1,690 2,800 0.70 0.52 0.86
South America 10,050 9,720 10,530 3.47 3.35 3.63 600 540 680 0.21 0.19 0.23 220 130 310 0.08 0.05 0.11
Asia 61,460 24,340 95,170 2.01 0.80 3.11 35,750 15,250 47,850 1.17 0.50 1.56 21,540 9,170 29,550 0.70 0.30 0.97
Central Asia and  
Transcaucasia
1,520 450 2,500 2.58 0.77 4.25 570 500 660 0.97 0.85 1.12 570 490 660 0.97 0.83 1.11
East and 
South-East Asia
19,330 8,710 24,010 1.19 0.54 1.48 3,290 2,420 4,020 0.20 0.15 0.25 3,290 2,420 4,020 0.20 0.15 0.25
South-West Asia/ 
Near and Middle East
10,780 7,740 12,830 3.34 2.40 3.98 10,310 8,480 12,840 3.19 2.63 3.98 5,690 4,090 8,050 1.76 1.27 2.49
South Asia 29,830 7,440 55,830 2.82 0.70 5.27 21,590 3,850 30,340 2.04 0.36 2.86 11,990 2,170 16,830 1.13 0.21 1.59




4,630 3,350 6,540 2.07 1.49 2.92 1,730 1,640 1,810 0.77 0.73 0.81 1,490 1,410 1,570 0.67 0.63 0.70
Western and 
Central Europe
24,980 24,910 25,050 7.83 7.81 7.85 1,880 1,790 1,990 0.59 0.56 0.62 1,590 1,490 1,700 0.50 0.47 0.53
Oceania 3,220 3,170 3,340 12.00 11.78 12.42 660 580 740 2.47 2.17 2.76 30 20 30 0.11 0.08 0.12
Australia and  
New Zealand
2,360 2,360 2,360 12.14 12.14 12.14 - - - - - - - - - - - -
Melanesia - - - - - - - - - - - - - - - - - -
Micronesia - - - - - - - - - - - - - - - - - -
Polynesia - - - - - - - - - - - - - - - - - -
GLOBAL ESTIMATE 200,380 141,430 256,400 3.98 2.81 5.09 61,650 36,940 78,260 1.22 0.73 1.55 30,780 15,370 44,040 0.61 0.31 0.87
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TABLE 2 Annual prevalence of the use of cocaine, amphetamine-type stimulants and “ecstasy”, by region and globally, 2019

























Africa 1,950 520 4,260 0.27 0.07 0.58 2,720 690 5,810 0.38 0.10 0.82 1,890 100 8,270 0.26 0.01 1.13
East Africa - - - - - - - - - - - - - - - - - -
North Africa 407 311 483 0.27 0.21 0.32 - - - - - - - - - - - -
Southern Africa - - - - - - - - - - - - - - - - - -
West and Central Africa 431 71 967 0.15 0.02 0.34 780 50 1,810 0.28 0.02 0.66 - - - - - -
Americas 10,360 9,180 11,470 1.54 1.36 1.70 8,710 8,190 9,460 1.30 1.22 1.41 3,620 3,460 3,790 0.54 0.51 0.56
Caribbean 180 80 320 0.63 0.29 1.14 - - - - - - 60 30 100 0.23 0.10 0.36
Central America 310 140 520 0.96 0.44 1.62 310 190 440 0.98 0.61 1.41 60 20 110 0.17 0.07 0.33
North America 6,880 6,740 7,030 2.12 2.08 2.17 7,380 7,330 7,420 2.29 2.27 2.30 2,890 2,880 2,890 0.89 0.89 0.89
South America 2,990 2,220 3,610 1.03 0.77 1.24 770 650 900 0.27 0.23 0.31 610 520 690 0.21 0.18 0.24
Asia 2,030 1,620 2,600 0.07 0.05 0.08 12,670 11,920 13,500 0.42 0.39 0.44 9,930 1,880 17,980 0.32 0.06 0.59
Central Asia  
and Transcaucasia
- - - - - - - - - - - - - - - - - -
East and 
South-East Asia
780 530 1,030 0.05 0.03 0.06 9,860 9,510 10,280 0.61 0.59 0.64 3,670 1,220 6,120 0.23 0.08 0.38
South-West Asia/ 
Near and Middle East
160 30 440 0.05 0.01 0.14 640 350 920 0.17 0.11 0.29 2,180 410 3,940 0.67 0.13 1.22
South Asia 1,060 1,060 1,060 0.10 0.10 0.10 1,970 1,960 1,970 0.19 0.19 0.19 - - - - - -
Europe 5,000 4,630 5,520 0.92 0.85 1.02 2,510 2,050 3,070 0.46 0.38 0.56 3,550 3,000 4,600 0.65 0.55 0.85
Eastern and  
South-Eastern Europe
580 220 1,070 0.26 0.10 0.48 - - - - - - 780 280 1,780 0.35 0.12 0.79
Western and  
Central Europe
4,430 4,410 4,450 1.39 1.38 1.39 1,950 1,700 2,300 0.61 0.53 0.72 2,770 2,720 2,820 0.87 0.85 0.89
Oceania 730 700 730 2.70 2.60 2.73 340 310 350 1.27 1.16 1.33 590 550 600 2.18 2.05 2.22
Australia and  
New Zealand
- - - - - - 240 240 250 1.26 1.22 1.30 550 540 560 2.84 2.79 2.90
Melanesia - - - - - - - - - - - - - - - - - -
Micronesia - - - - - - - - - - - - - - - - - -
Polynesia - - - - - - - - - - - - - - - - - -

















TABLE 3 Estimated number and prevalence (percentage) of people who inject drugs and those living with HIV among this group,  
by region, 2019
 
Sources: Responses to the annual report questionnaire; progress reports of the Joint United Nations Programme on HIV/AIDS (UNAIDS) on the global AIDS response (various years);  
the former Reference Group to the United Nations on HIV and Injecting Drug Use; published peer-reviewed articles; and government reports.
Note: Prevalence of people who inject drugs is the percentage of the population aged 15–64 years.
Region or
subregion
People who inject drugs HIV among people who inject drugs








Data coverage  
of estimated number 
of people who 
inject drugsLow Best High Low Best High Low Best High
Africa 590,000 950,000 1,760,000 0.08 0.13 0.24 67.9% 52,000 103,000 300,000 10.9 82.9%
East Africa 90,000 260,000 680,000 0.05 0.13 0.35 58.8% 11,000 43,000 124,000 16.3 87.6%
 West and Central Africa 280,000 360,000 520,000 0.10 0.13 0.18 77.2% 14,000 17,000 27,000 4.6 88.5%
 Southern Africa 100,000 150,000 180,000 0.10 0.14 0.17 62.9% 21,000 32,000 63,000 21.8 59.2%
 North Africa 110,000 180,000 390,000 0.08 0.12 0.26 65.6% 6,000 12,000 86,000 6.7 83.8%
America 1,880,000 2,350,000 2,920,000 0.28 0.35 0.43 87.3% 112,000 176,000 269,000 7.5 93.6%
 North America 1,590,000 1,800,000 2,020,000 0.49 0.56 0.62 100% 96,000 125,000 158,000 6.9 100%
 Caribbean 40,000 90,000 210,000 0.14 0.33 0.76 31.3% 4,000 13,000 26,000 14.0 31.8%
South America 240,000 440,000 660,000 0.08 0.15 0.23 81.9% 12,000 37,000 83,000 8.5 82.9%
Central America 10,000 20,000 30,000 0.04 0.06 0.09 57.7% 300 600 1,400 3.4 32.9%
Asia 3,920,000 5,210,000 6,530,000 0.13 0.17 0.21 95.1% 382,000 588,000 821,000 11.3 98%
Central Asia and  
Transcaucasia
350,000 370,000 400,000 0.59 0.63 0.68 93.5% 23,000 26,000 31,000 7.0 93.5%
East and  
South-East Asia
1,970,000 3,030,000 4,000,000 0.12 0.19 0.25 95.1% 135,000 277,000 434,000 9.1 98.7%
South-West Asia 620,000 760,000 910,000 0.30 0.36 0.43 100% 163,000 218,000 275,000 28.6 100%
Near and Middle East 40,000 90,000 260,000 0.03 0.08 0.23 42% 1,800 3,300 10,600 3.8 55.4%
South Asia 950,000 950,000 960,000 0.09 0.09 0.09 100% 59,000 64,000 70,000 6.7 100%
Europe 2,370,000 2,570,000 2,830,000 0.44 0.47 0.52 90% 514,000 537,000 573,000 20.9 100%
Eastern Europe 1,690,000 1,710,000 1,740,000 1.24 1.26 1.27 100% 437,000 447,000 457,000 26.1 100%
South-Eastern Europe 80,000 90,000 130,000 0.09 0.11 0.15 100% 4,900 5,800 7,700 6.2 100%
Western and 
Central Europe
600,000 770,000 960,000 0.19 0.24 0.30 83% 73,000 84,000 108,000 11.0 99.9%
Oceania 100,000 100,000 110,000 0.37 0.38 0.41 72.3% 1,400 1,800 2,000 1.8 72.3%

















TABLE 4 Illicit cultivation of opium poppy, 2009–2020 (hectares)
Sources: Afghanistan: Until 2018, Afghanistan Opium Surveys were conducted by the Ministry of Counter-Narcotics (MCN) of Afghanistan and the United Nations Office on Drugs and 
Crime (UNODC). Data for 2019-2020 was obtained from the UNODC Illicit Crop Monitoring Programme.
Lao People’s Democratic Republic: Up till 2015, national illicit crop monitoring system supported by the United Nations Office on Drugs and Crime (UNODC). Data from 2016 onwards 
from Lao National Commission for Drug Control and Supervision.
Myanmar: national illicit crop monitoring system supported by the United Nations Office on Drugs and Crime (UNODC). 
Colombia: Government of Colombia.  
Mexico: up to 2014, estimates derived from surveys by the Government of the United States of America (international narcotics control strategy reports); for 2015 onwards, joint Mexico/
UNODC project entitled “Monitoring of the illicit cultivation on Mexican territory”. 
Note: Two dots indicate that data were unavailable. Information on estimation methodologies and definitions can be found in the online methodology section of the World Drug Report 2021.
a) Bound of the statistically derived confidence interval.
b) May include areas that were eradicated after the date of the area survey. 
c) In 2020, the opium poppy cultivation survey covered Shan and Kachin States.  46 sample locations 
were available in Shan and Kachin States (compared to 84 locations in 2019), which increased 
uncertainty around area and production estimates. Estimates for 2014, 2015, 2018 included area 
estimates for Kayah and Chin states. In the absence of information on Kayah and Chin, the 2019, 2020 
national area estimate uses latest available cultivation estimates (2018) for Chin and Kayah states. 
National estimates for 2014, 2015, 2018, 2019, 2020 are therefore not directly comparable with other 
years. 
d) Up to 2014, the estimates for Mexico are sourced from the Department of State of the United States. 
The Government of Mexico does not validate the estimates provided by the United States as they are not 
part of its official figures and it does not have information on the methodology used to calculate them.
e) The figures for 2015, as published in the World Drug Report 2016 (United Nations publication, Sales 
No. E.16.XI.7),  have been revised owing to a statistical adjustment processed by UNODC. The 2015 
figures refer to the period July 2014–June 2015 and are not comparable with subsequent years, due to 
the updates in the methodology implemented from the 2015–2016 period onwards.  
f) The figures for 2016, 2017, 2018 and 2019 are based on the estimation periods July 2015–June 2016,  
July 2016–June 2017 and July 2017–June 2018, July 2018–June 2019 respectively.
g) Data from 2016 onwards are not comparable to prior years.
h) Data for 2018 from U.S. State Department, International Narcotics Control Strategy Report 2020. 
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
 SOUTH-WEST ASIA
Afghanistan  
(best estimate) 123,000 123,000 131,000 154,000 209,000 224,000 183,000 201,000 328,000 263,000 163,000 224,000
lower bound a 102,000 104,000 109,000 125,000 173,000 196,000 163,000 182,000 301,000 242,000 149,000 202000
upper bound a 137,000 145,000 155,000 189,000 238,000 247,000 202,000 221,000 355,000 283,000 178,000 246000
 SOUTH-EAST ASIA
Lao People’s  
Democratic Republic  
(best estimate) b, g
1,900 3,000 4,100 6,800 3,900 6,200 5,700 5,395 5,327 4,925 4,624 ..
lower bound a 1,100 1,900 2,500 3,100 1,900 3,500 3,900
upper bound a 2,700 4,000 6,000 11,500 5,800 9,000 7,600
Myanmar  
(best estimate) b, c 31,700 38,100 43,600 51,000 57,800 57,600 55,500 .. 41,000 37,300 33,100 29,500
lower bound a 20,500 17,300 29,700 38,249 45,710 41,400 42,800  30,200  29,700 25,800 21,000
upper bound a 42,800 58,100 59,600 64,357 69,918 87,300 69,600  51,900  47,200 42,800 50,400
 SOUTH AND CENTRAL AMERICA
Colombia  
(best estimate) 356 341 338 313 298 387 595 462 282 663 .. ..
Mexico  
(best estimate) d, e, f 19,500 14,000 12,000 10,500 11,000 17,000 26,100 25,200 30,600 28,000 21,500 ..
lower bound a 21,800 20,400 22,800 21,200 15,500
upper bound a 30,400 30,000 38,400 34,800 27,500
OTHER
Other countries e 9,479 12,221 16,390 12,282 13,293 11,585 8,549 54,641 8,792 11,815 14,656 40,855
TOTAL (best estimate) 185,935 190,662 207,428 234,895 295,291 316,772 279,444 286,698 414,001 345,703 236,880 294,355
  lower bound 152,935 149,762 169,928 189,444 245,201 269,872 240,644 257,996 368,401 310,021 211,619 259,894
  upper bound 211,835 233,662 249,328 287,952 338,309 372,272 318,744 333,396 459,701 382,121 247,587 323,187
TOTAL  

















TABLE 5 Potential production of oven–dry opium, 2009–2020 (tons)
Sources: Afghanistan: Until 2018, Afghanistan Opium Surveys were conducted by the Ministry of Counter-Narcotics (MCN) of Afghanistan and the United Nations Office on Drugs and 
Crime (UNODC). Data for 2019 was obtained from the UNODC Illicit Crop Monitoring Programme.
Lao People’s Democratic Republic and Myanmar: national illicit crop monitoring system supported by the United Nations Office on Drugs and Crime (UNODC).
Colombia: National illicit crop monitoring system supported by UNODC. Since 2008, production was calculated based on updated regional yield figures and conversion ratios from the 
Department of State and the Drug Enforcement Administration of the United States of America. 
Mexico: Up till 2014, estimates derived from surveys by the United States Government; from 2015 onwards national illicit crop monitoring system supported by UNODC.
Note: Two dots indicate that data were unavailable. Information on estimation methodologies and definitions can be found in the online methodology section of the World Drug Report 2021.  
a) Bound of the statistically derived confidence interval.
b) Based on cultivation figures which may include areas eradicated after the date of the area survey.
c) Up to 2014, the estimates are sourced from the Department of State of the United States. The 
Government of Mexico does not validate the estimates provided by the United States as they are not part 
of its official figures and it does not have information on the methodology used to calculate them.
e) The figures from 2015 on have been updated with newly available data. The joint Mexico/UNODC 
project “Monitoring of the illicit cultivation on Mexican territory” collected yield data for the first time in 
the 2017/2018 period. The production figures presented are based on: (1) annual estimates of area under 
cultivation, established by the joint project of the Government of Mexico and UNODC; (2) yield data 
collected in an initial survey in the 2017/2018 period. UNODC and Mexico are jointly working on 
continuously expanding the scope and quality of yield data collected. For methodological reasons, the 
figures shown for 2015-2018 are not comparable with the  figures over the period 1998-2014.
f) Production estimates for the period 2016–2019 are based on cultivation estimates for the period 
2016–2019 and average yields per ha reported over the 2012–2014 period.
g) Bound of the statistically derived confidence interval, with the exception of 2015. The figures for 2015 
represent independently derived upper and lower estimates; the midpoint was used for the calculation of 
the global total.
h) Estimates for 2014, 2015, 2018 include estimates for Kayah and Chin states. In the absence of 
information on Kayah and Chin, the 2019 national potential production estimate uses latest available 
(2018) cultivation estimates for Kayah and Chin states and the 2019 weighted national average yield 
(15.4 kg/ha). National estimates for 2014, 2015, 2018 and 2019 are therefore not directly comparable 
with other years.
i) The figures for 2015, 2016, 2017,  2018, and 2019 are based on the estimation periods July 2014–June 
2015, July 2015–June 2016, July 2016–June 2017, July 2017–June 2018, and July 2018–June 2019 
respectively.
j) Data on the potential opium production for 2019 and 2020 was obtained brom the UNODC Illicit 
Crop Monitoring Programme. The same methodology was used as in previous years for yield 
measurement and estimation of potential opium production. The results for the year 2019 were not 
validated by the Government of Afghanistan and are not recognized by the Government as its official 
estimate.
k) Production estimates for 2018 based on cultivation estimates by the U.S. State Department 
International Narcotics Control Strategy Report 2020 and average yields reported for the years 
2015–2017.
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
 SOUTH-WEST ASIA
Afghanistan  
(best estimate) j 4,000 3,600 5,800 3,700 5,500 6,400 3,300 4,800 9,000 6,400 6,400 6,300
  lower bound a 3,000 4,800 2,800 4,500 5,100 2,700 4,000 8,000 5,600 5,600 5,400
  upper bound a 4,200 6,800 4,200 6,500 7,800 3,900 5,600 10,000 7,200 7,100 7,200
 SOUTH-EAST ASIA
Lao People’s Democratic 
Republic (best estimate) b, f 11 18  25 41 23 92 .. 48 48 44 41 ..
  lower bound g 7 11 15 18 11 51 84
  upper bound g 16 24 36 69 35 133 176
Myanmar (best estimate) b, h 330 580  610 690 870 670 647h .. 550 520 508 405
  lower bound  213  350  420  520  630 481 500 395 410 380 289
  upper bound  445  820  830  870  1,100 916 820 706 664 672 685
SOUTH AND CENTRAL AMERICA
Colombia (best estimate) k 9 8 8 8 11 12 17 13 7 18 .. ..
Mexico (best estimate) c, e, i 425 300 250 220 225 360 419 404 492 450 440 ..
  lower bound a 265 251 288 267 286
  upper bound a 572 557 695 633 595
OTHER
Other countries  
(best estimate) d 178 224 290 172 182 201 147 711 143 168 227 708
TOTAL (best estimate) 4,953 4,730 6,983 4,831 6,810 7,735 4,659 5,976 10,239 7,600 7,616 7,413
  lower bound (published) 3,894 5,783 3,738 5,558 6,205 3,713 4,927 8,881 6,507 6,670 6,467
  upper bound 5,576 8,214 5,539 8,052 9,423 5,632 7,153 11,599 8,727 8,462 8,259
TOTAL  











Notes: The calculation shows the potential amount of heroin that could have been manufactured out of the opium produced in a given year; it does not take into account changes in opium inventories, which may 
add to or reduce the amount of heroin entering the market in that year. Afghanistan and Myanmar are the only countries for which the proportion of potential opium production not converted into heroin within 
the country is estimated. For Myanmar, these estimates were available only for 2018 and 2019. For all other countries, for the purposes of this table, it is assumed that all opium produced is converted into heroin. 
The amount of heroin produced from Afghan opium is calculated using two parameters that may change: (a) the amounts of opium consumed as raw opium in the region; and (b) the conversion ratio into heroin. 
The first parameter’s estimate is based on consumption data in Afghanistan and neighbouring countries. For the second parameter, from 2005 to 2013, a conversion ratio of opium to morphine/heroin of 7:1 was 
used, based on interviews conducted with Afghan morphine/heroin “cooks”, on an actual heroin production exercise conducted by two (illiterate) Afghan heroin “cooks”, documented by the German Bundeskrimi-
nalamt in Afghanistan in 2003 (published in Bulletin on Narcotics, vol. LVII, Nos. 1 and 2, 2005, pp. 11–31), and United Nations Office on Drugs and Crime (UNODC) studies on the morphine content of Afghan 
opium (12.3 per cent over the period 2010–2012, down from 15 per cent over the period 2000–2003). Starting from 2014, a different approach to the conversion was adopted, reflecting updated information on 
morphine content and a different method for taking purity into account. The revised approach uses a ratio of 18.5 (range: 17.5–19.6) kg of opium for 1 kg of 100 per cent pure heroin base (see Afghanistan Opium 
Survey 2014, UNODC, November 2014). In addition, the conversion into export-quality heroin assumes purity to be between 50 and 70 per cent. For more details, see “Afghanistan Opium Survey 2017 
– Challenges to sustainable development, peace and security” (UNODC, May 2018).
The amount of heroin produced in Myanmar in 2018 , 2019 and 2020 was calculated by subtracting the estimated unprocessed opium for consumption from the total opium production and using a conversion 
factor of 10:1. The unprocessed opium in Myanmar was based on the total unprocessed opium in East Asia and the relative cultivation levels of Lao PDR and Myanmar (see Transnational Organized Crime in East 
Asia and the Pacific – A Threat Assessment, UNODC, 2013 and Transnational Organized Crime in Southeast Asia: Evolution, Growth and Impact 2019, UNODC, 2019). For further information, please refer to the 
Methodology chapter (section 4.3) of the Myanmar Opium Survey 2018 (UNODC, January 2019) and the Myanmar Opium Survey 2019 (UNODC, February 2020).  
For countries other than Afghanistan, a “traditional” conversion ratio of opium to heroin of 10:1 is used. The ratios will be adjusted when improved information becomes available. Figures in italics are preliminary 
and may be revised when updated information becomes available.
TABLE 6 Global manufacture of heroin from global illicit opium production, 2009–2020 (tons)
TABLE 7 Global illicit cultivation of coca bush, 2009–2019 (hectares)
2009 2010 2011 2012 2013 1905 2015 2016 2017 2018 2019
Bolivia 
(Plurinational State of) 30,900 31,000 27,200 25,300 23,000 20,400 20,200 23,100  24,500  23,100  25,500 
Colombia a 73,000 62,000 64,000 48,000 48,000 69,000 96,000 146,000  171,000  169,000  154,000 
Peru b 59,900 61,200 64,400
Peru c 62,500 60,400 49,800 42,900 40,300 43,900  49,900  54,100  54,700 
Total 163,800 154,200 155,600d 133,700 120,800 132,300 156,500 213,000 245,400 246,200 234,200 
Sources: Plurinational State of Bolivia: national illicit crop monitoring system supported by the United Nations Office on Drugs and Crime (UNODC). Colombia: national illicit crop 
monitoring system supported by UNODC. Peru: national illicit crop monitoring system supported by UNODC.
Note: Different area concepts and their effect on comparability were presented in the World Drug Report 2012 (United Nations publication, Sales No. E.12.XI.1) (p. 41–42). Efforts to improve the comparability of 
estimates between countries continue; since 2011 the net area under coca bush cultivation on the reference date of 31 December was estimated for Peru, in addition to Colombia. The estimate presented for the 
Plurinational State of Bolivia represents the area under coca cultivation as interpreted on satellite imagery.       
a) Net area on 31 December.          
b) Figures represent the area under coca cultivation as interpreted on satellite imagery (without deductions for subsequent eradication).   
c) Net area on 31 December, deducting fields eradicated after satellite imagery was taken.         
d) The global coca cultivation figure was calculated with the “area as interpreted on satellite imagery” for Peru in 2011.       
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Total potential  
opium production  4,953  4,730  6,983  4,831  6,810  7,735  4,659  5,976  10,270  7,618  7,616 7,413
Potential opium not  
processed into heroin  1,680  1,728  3,400  1,850  2,600  2,450  1,360  2,510  1,100–1,400  1,225–1,525  1,180–1,480  1,177–1,477 
Potential opium  
processed into heroin  3,273  3,002  3,583  2,981  4,210  5,285  3,299  3,466  8,870–9,170  6,093–6,393  6,136–6,436  5,936–6,236 
Total potential  

















Source: United Nations Office on Drugs and Crime annual report questionnaire and government reports.
Note: The totals for Bolivia (Plurinational State of) and Peru include voluntary and forced eradication. Reported eradication refers to the sum of all areas eradicated in a year, including repeated eradication of the 
same fields. Two dots indicate that data are not available.          
TABLE 8 Reported eradication of coca bush, 2009–2019
Sources: Plurinational State of Bolivia: calculations based on coca leaf yield surveys by the United Nations Office on Drugs and Crime (UNODC) (Yungas de La Paz) and scientific studies by 
the Drug Enforcement Administration of the United States of America (Chapare). Colombia: UNODC/Government of Colombia. Peru: calculations based on coca leaf to cocaine 
conversion ratio from scientific studies by the Drug Enforcement Administration.       
Notes: Figures in italics are subject to revision. Two dots indicate that data are not available. Information on estimation methodologies and definitions can be found in the online methodology section of the World 
Drug Report 2021.            
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Bolivia 
(Plurinational State of) a .. .. .. .. .. .. .. .. .. .. ..
Colombia b, c, d 488 424 384 333 290 368 499 810 1,058 1,120 1,137 
Peru a .. .. .. .. .. .. .. .. .. .. ..
Total b, c, d  1,188  1,134  1,090  997  902  869  977  1,335  1,647  1,723  1,784 
TABLE 9 Potential manufacture of 100 per cent pure cocaine, 2009–2019 (tons)
a) Owing to a lack of updated conversion factors in Bolivia (Plurinational State of) and Peru, no final 
estimates of the level of cocaine production can be provided. Detailed information on the ongoing 
revision of conversion ratios and cocaine laboratory efficiency is available in the World Drug Report 2010 
(United Nations publication, Sales No. E.10.XI.13), p. 249.  
b) Values for Colombia for 2014–17 have been revised, using an improved methodology, to take into 
account the participation of new actors in the processing chain from coca leaf to cocaine. The same 
methodology was used for 2018. Thus, the values for 2014-18, and hence the global total for the same 
years, may not be directly comparable to earlier years. 
c) Conversion of areas under coca cultivation into coca leaf and then into cocaine hydrochloride, taking 
yields, amounts of coca leaf used for licit purposes and cocaine laboratory efficiency into account. 
Current global aggregates are based on “new” conversion ratios representing the most recent data 
available to UNODC. See World Drug Report 2010 (United Nations publication, Sales No. E.10.XI.13, p. 
249)  for a discussion of “new” and “old” conversion factors and detailed information on the ongoing 
revision of conversion ratios and cocaine laboratory efficiency.
d) With respect to data published in the World Drug Report 2016 (United Nations publication, Sales No. 
E.16.XI.7), the following amendments have been made: 
(i) totals for 2009–2012 have been revised to rectify minor inaccuracies in data processing.
Method of 
eradication Unit 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Bolivia  
(Plurinational State of) manual hectare 6,341 8,200 10,509 11,044 11,407 11,144 11,020 6,577 7,237 11,174 9,205
Colombia manual hectare 60,565 43,804 35,201 30,456 22,121 11,703 13,473 17,642 52,001 59,978 94,606
spraying hectare 104,772 101,940 103,302 100,549 47,052 55,532 37,199 0 0 0 0
Peru manual hectare 10,025 12,033 10,290 14,171 23,785 31,205 35,868 30,150 23,025 25,107 25,526
Ecuador manual hectare 6 3 14 .. .. .. .. .. .. .. ..















TABLE 10 Cannabis cultivation, production and eradication, latest year available from the period 2013–2019















2012 Afghanistan resin outdoors  10,000  1,400 
2016 Albania herb outdoors  2,536,288  5,205 
2017 Albania herb Indoors  7,766 
2017 Albania herb outdoors  66,927  500 
2017 Albania herb outdoors  33,177  379 
2018 Albania herb Indoors  2,716 
2014 Algeria resin outdoors  2,522 
2016 Armenia herb outdoors 0.50 a 0.50 0.00 757 20
2017 Armenia herb outdoors 0.50 a 0.50 0.00 2,547 21
2018 Armenia herb Indoors 1,025 36
2016 Australia herb indoors 31,266 408
2016 Australia herb outdoors 22,257 1,021
2017 Australia herb indoors 78,310 433
2017 Australia herb outdoors 1.00 a 1.00 0.00 31,431 948
2018 Australia herb indoors 38,492 542
2018 Australia herb outdoors 0.80 a 0.80 0.00 19,981 1,120
2015 Austria herb outdoors 3.00 a 3.00 0.00
2013 Azerbaijan herb outdoors 23.95 a 23.95 0.00 263.96 8,469 151
2014 Azerbaijan herb outdoors 17.50 a 17.50 0.00 14,889 195
2017 Azerbaijan herb outdoors 0.25 a 0.25 336,791
2015 Bahamas herb outdoors 17,270
2012 Bangladesh herb outdoors 39,848
2013 Bangladesh herb outdoors 35,012
2014 Bangladesh herb outdoors 35,988
2015 Bangladesh herb outdoors 39,967
2016 Bangladesh herb outdoors 47,104
2017 Bangladesh herb outdoors 69,989
2016 Belarus herb indoors 28
2016 Belarus herb oudoors 123.80 1,945
2017 Belarus herb indoors 32
2017 Belarus herb oudoors 125.90 2,283
2018 Belarus herb indoors 42
2018 Belarus herb oudoors 106.30 2,469
2015 Belgium herb indoors 345,518 1,164
2015 Belgium herb outdoors 4,885 93
2017 Belgium herb indoors 415,728 1,175
2017 Belgium herb outdoors 848 59
2018 Belgium herb indoors 421,326 944
2018 Belgium herb outdoors 935 62
2015 Belize herb outdoors 50,897
2017 Bhutan herb outdoors 1.00 a 1.00 0.00 100,000 12
2016 Bolivia (Plurinational State of) herb outdoors 14.60 35
2017 Bolivia (Plurinational State of) herb outdoors 14.00 52
2018 Bolivia (Plurinational State of) herb outdoors 13.36 52
2016 Bosnia and Herzegovina herb indoors 39.00
2016 Bosnia and Herzegovina herb outdoors 1,680.00
2017 Bosnia and Herzegovina herb indoors 1 1
2017 Bosnia and Herzegovina herb outdoors 0.02 a 0.02 0.00 539 53































2018 Bosnia and Herzegovina herb outdoors 0.02 a 0.02 0.00 1,580 12
2014 Brazil herb outdoors 44.01  1,364,316 
2017 Brazil herb outdoors 117.51  1,910,451 604
2018 Brazil herb outdoors 68.31  968,145 
2015 Bulgaria herb indoors 323
2015 Bulgaria herb outdoors 37.77 9,488
2017 Central African Republic herb outdoors 130.00 60.00 55 10.00  250,000 22
2016 Chile herb indoors 26,988 2,740
2016 Chile herb outdoors 58,950 264
2017 Chile herb indoors 50,414 2,408
2017 Chile herb outdoors 194,694 202
2018 Chile herb indoors 66,007 2,357
2018 Chile herb outdoors 183,185 318
2016 China herb outdoors 9.80 1,390,000
2018 China herb outdoors 710
2016 Colombia herb outdoors 135.00
2017 Colombia herb outdoors 173.71
2018 Colombia herb outdoors 59.66
2016 Costa Rica herb indoors 678.00 5
2016 Costa Rica herb outdoors 17.59 2,122,244 201
2017 Costa Rica herb indoors 2
2017 Costa Rica herb outdoors 14.30 215
2018 Costa Rica herb indoors 4
2018 Costa Rica herb outdoors 11.41 11.41 1,346,273 208
2016 Côte d’Ivoire herb outdoors 5
2017 Côte d’Ivoire herb outdoors 0.25 1
2018 Côte d’Ivoire herb outdoors 104 1
2016 Czechia herb indoors 53,549 229
2016 Czechia herb outdoors 4,111
2017 Czechia herb indoors 50,925 305
2017 Czechia herb outdoors 3,467
2018 Czechia herb outdoors 6,581
2015 Denmark herb indoors/outdoors 14,560 97
2016 Denmark herb indoors/outdoors 13,217 105
2017 Denmark herb indoors/outdoors 34,801 65
2014 Dominican Republic herb outdoors 6.00 a 6.00 0.00 0.21 111 8
2016 Ecuador herb outdoors 224 34
2017 Ecuador herb outdoors 397 10
2018 Ecuador herb indoors 127 30
2018 Ecuador herb outdoors 13,891 4
2015 Egypt herb/resin outdoors 140.00
2017 Egypt herb/resin outdoors 126.00
2018 Eswatini herb outdoors 1,500.00 1,069.50 430.50 3,000,000 210
2017 Georgia herb indoors 0.01 186 91
2017 Georgia herb outdoors 0.02 a 0.02 0.00 93 19
2016 El Salvador herb outdoors 1.00 227 25
2014 France herb outdoors 158,592 837
2018 France herb outdoors 138,561
2017 Georgia herb indoors 0.01 186 91
2017 Georgia herb outdoors 0.02 0.02 0.00 93 19




























2018 Georgia herb outdoors 0.10 0.10 0.00 406 98
2015 Germany herb indoors 135,925 786
2015 Germany herb outdoors  9,136 127
2017 Germany herb indoors 85,226 573
2017 Germany herb outdoors 95
2016 Greece herb indoors  16,554 
2016 Greece herb oudoors  39,151 
2017 Greece herb indoors  19,498 
2017 Greece herb oudoors  27,409 
2018 Greece herb indoors  6,913 
2018 Greece herb oudoors  43,684 
2016 Guatemala herb outdoors 9.00  3,138,298 427
2017 Guatemala herb outdoors 3.50 a 3.81 1.61  6,033,345 150
2018 Guatemala herb outdoors 129.00 a 129.00 0.00  5,189,422 368
2015 Guyana herb outdoors 20.00 9.40 10.60 1,000.00  419,700 19
2016 Honduras herb indoors  7 2
2016 Honduras herb oudoors  24,253 19
2017 Honduras herb oudoors 59.58 a 59.59 0.00
2018 Honduras herb oudoors  720,426 67
2016 China, Hong Kong SAR herb indoors  329 1
2016 Hungary herb indoors 5,000 3
2016 Hungary herb outdoors 2,000 20
2013 Iceland herb indoors 6,652 323
2016 India herb outdoors 3,414.74
2017 India herb outdoors 3,445.90 6,687,376
2018 India herb outdoors 3,430.12
2016 Indonesia herb outdoors 482.00 a 482.00 0.00
2017 Indonesia herb outdoors 89.00 a 89.00 0.00 738,020 14
2018 Indonesia herb outdoors 76.23 a 76.23 0.00 1,455,390 13
2018 Iran (Islamic Republic of) herb indoors 0.04
2016 Ireland herb indoors 7,273
2017 Ireland herb indoors 9,046 50
2018 Ireland herb indoors 7,186
2014 Italy herb indoors 51,534 639
2014 Italy herb outdoors 70,125 1,134
2017 Italy herb indoors 56,125 1,161
2017 Italy herb outdoors 209,510 401
2012 Jamaica herb outdoors 456 382
2016 Kazakhstan herb outdoors 18.00 a 18.00 0.00 170,000 202
2017 Kazakhstan herb outdoors 12.30 a 12.30 0.00 930,774 91
2016 Kenya herb outdoors 12.00 8,747 46
2017 Kenya herb outdoors 0.10 4,662
2018 Kenya herb outdoors 0.10 517
2015 Kyrgyzstan herb outdoors 5,014.00 5,014.00
2018 Kyrgyzstan herb outdoors 1,276.37 457.69 818.68 49,942 12.00
2016 Latvia herb indoors 557 35
2016 Latvia herb outdoors 78 6
2017 Latvia herb indoors 798 34
2017 Latvia herb outdoors 66 15
2018 Latvia herb indoors 152 17































2015 Lebanon herb outdoors 3,500.00 3,500.00
2017 Lebanon Kif outdoors 40,772.00
2018 Lebanon herb outdoors 4,205.70 4,205.70
2016 Lithuania herb indoors 4
2017 Lithuania herb indoors 8
2017 Lithuania herb outdoors 7
2018 Lithuania herb indoors 3
2015 Madagascar herb outdoors 11.00 21,325
2017 Madagascar herb outdoors 9.00 57,708
2013 Malta herb indoors 27
2016 Mexico herb outdoors 5,478.42 6,574.1 38,432
2017 Mexico herb outdoors 4,193.34 5,032.0 34,523
2018 Mexico herb outdoors 2,263.71 2,716.47 28,873
2013 Mongolia herb outdoors 15,000.00 4,000.00 11,000.00 4,000 4,000
2018 Mongolia herb outdoors 15,000.00 173.00 14,827.00 33
2016 Morocco herb outdoors 35,652.83
2016 Morocco plant outdoors 47,000.00 395.00 46,605.00
2016 Morocco resin outdoors 713.00
2017 Morocco herb outdoors 35,702.90
2017 Morocco plant outdoors 47,500.00 523.00 46,977.00
2017 Morocco resin outdoors 714.06
2018 Morocco herb outdoors 23,699.80
2018 Morocco plant outdoors 47,500.00 47,500.00
2018 Morocco resin outdoors 423.58
2014 Myanmar herb outdoors 15.00 10.00 5.00 3
2018 Nepal herb outdoors 235.87 235.87 0.00 5,000.00 2,358,700 335
2016 Netherlands herb indoors 994,068 5,856
2017 Netherlands herb indoors 883,163 5,538
2018 Netherlands herb indoors 516,418 3,482
2018 Netherlands herb outdoors 431
2016 New Zealand herb indoors 18,903 607
2016 New Zealand herb outdoors 104,725
2017 New Zealand herb indoors 19,992
2017 New Zealand herb outdoors 19,559
2018 New Zealand herb indoors 19,313
2018 New Zealand herb outdoors 22,660
2014 Nicaragua herb outdoors 0.30 1,507.00 3,014 30
2016 Nicaragua herb outdoors 275,000
2017 Nicaragua herb outdoors 994,787
2016 Nigeria herb outdoors 718.78 65
2017 Nigeria herb outdoors 317.12
2018 Nigeria herb outdoors 3,660.64
2015 Norway herb indoors 0.04 4,000 30
2017 North Macedonia herb indoors 168
2017 North Macedonia herb outdoors 220
2018 North Macedonia herb outdoors 2.51 4.04 2,264 4,527
2016 Oman herb outdoors 0.50 a 0.50 0.00 5 3
2013 Panama herb indoors 0.50 a 0.50 0.00 37 2
2013 Panama herb outdoors 10.50 a 10.50 0.00 78,633 2
2016 Paraguay herb outdoors 1,298.50




























2016 Paraguay resin outdoors 1.15
2017 Paraguay plant outdoors 1,462.00 36,550,000
2016 Peru herb outdoors 87.83 1,429,749
2017 Peru herb outdoors 61.30 4,671,387 47
2018 Peru herb outdoors 91.80 1,716,751 46
2016 Philippines herb outdoors 8.67 24,635,153 337
2017 Philippines herb outdoors 4.82 221,035 27
2018 Philippines herb outdoors 12.39 869,682 186
2016 Poland herb indoors 146,755 1,403
2016 Poland herb indoors/outdoors 4,585 219
2017 Poland herb indoors 448 10
2017 Poland herb indoors/outdoors 54
2018 Poland herb indoors/outdoors 118,382 1,274
2017 Portugal herb indoors/outdoors 22,910 158
2018 Portugal herb indoors/outdoors 8,706 139
2013 Republic of Korea herb outdoors 8,072
2014 Republic of Moldova herb outdoors  100.00 59.00 41.00 10,000.00 200,548
2017 Republic of Moldova herb outdoors  0.15 2.57 257,236
2018 Republic of Moldova herb outdoors 0.71 86,926 61
2014 Republic of Moldova herb indoors 41.00
2016 Romania herb indoors 1,433 41
2016 Romania herb outdoors 6.99 42
2017 Romania herb indoors 1,875 46
2017 Romania herb outdoors 1.90 4,905 32
2018 Romania herb indoors 3,903 39
2018 Romania herb outdoors 0.11 1,882 98
2016 Russian Federation herb indoors 0.66 788
2016 Russian Federation herb outdoors 7.61 a 7.61 0.00 68.64 1,143
2016 Albania herb outdoors  2,536,288  5,205 
2017 Albania herb Indoors  7,766 
2017 Albania herb outdoors  66,927  500 
2017 Albania herb outdoors  33,177  379 
2018 Albania herb Indoors  2,716 
2014 Algeria resin outdoors  2,522 
2016 Armenia herb outdoors 0.50 a 0.50 0.00 757 20
2017 Armenia herb outdoors 0.50 a 0.50 0.00 2,547 21
2018 Armenia herb Indoors 1,025 36
2016 Australia herb indoors 31,266 408
2016 Australia herb outdoors 22,257 1,021
2017 Australia herb indoors 78,310 433
2017 Australia herb outdoors 1.00 a 1.00 0.00 31,431 948
2018 Australia herb indoors 38,492 542
2018 Australia herb outdoors 0.80 a 0.80 0.00 19,981 1,120
2019 Australia herb indoors 1.72 50,837 86
2019 Australia herb outdoors 0.04 a 0.04 0.00 4,755 1
2015 Austria herb outdoors 3.00 a 3.00 0.00
2013 Azerbaijan herb outdoors 23.95 a 23.95 0.00 263.96 8,469 151
2014 Azerbaijan herb outdoors 17.50 a 17.50 0.00 14,889 195
2017 Azerbaijan herb outdoors 0.25 a 0.25 336,791
2015 Bahamas herb outdoors 17,270































2014 Bangladesh herb outdoors 35,988
2015 Bangladesh herb outdoors 39,967
2016 Bangladesh herb outdoors 47,104
2017 Bangladesh herb outdoors 69,989
2016 Belarus herb indoors 28
2016 Belarus herb oudoors 123.80 1,945
2017 Belarus herb indoors 32
2017 Belarus herb oudoors 125.90 2,283
2018 Belarus herb indoors 42
2018 Belarus herb oudoors 106.30 2,469
2019 Belarus herb indoors 28
2019 Belarus herb oudoors 117.60 2,182
2015 Belgium herb indoors 345,518 1,164
2015 Belgium herb outdoors 4,885 93
2016 Belgium herb indoors 327,216 1,012
2016 Belgium herb outdoors 1,395 34
2017 Belgium herb indoors 415,728 1,175
2017 Belgium herb outdoors 848 59
2018 Belgium herb indoors 421,326 944
2018 Belgium herb outdoors 935 62
2015 Belize herb outdoors 50,897
2017 Bhutan herb outdoors 1.00 a 1.00 0.00 100,000 12
2016 Bolivia (Plurinational State of) herb outdoors 14.60 35
2017 Bolivia (Plurinational State of) herb outdoors 14.00 52
2018 Bolivia (Plurinational State of) herb outdoors 13.36 52
2019 Bolivia (Plurinational State of) herb outdoors 22.50 50
2016 Bosnia and Herzegovina herb indoors 39.00
2016 Bosnia and Herzegovina herb outdoors 1,680.00
2017 Bosnia and Herzegovina herb indoors 1 1
2017 Bosnia and Herzegovina herb outdoors 0.02 a 0.02 0.00 539 53
2018 Bosnia and Herzegovina herb indoors 0.02 a 0.02 0.00 6
2018 Bosnia and Herzegovina herb outdoors 0.02 a 0.02 0.00 1,580 12
2019 Bosnia and Herzegovina herb outdoors 30.00 a
2014 Brazil herb outdoors 44.01  1,364,316 
2017 Brazil herb outdoors 117.51  1,910,451 604
2018 Brazil herb outdoors 68.31  968,145 
2019 Brazil herb outdoors 74.53 475.70  1,585,759 651
2015 Bulgaria herb indoors 323
2015 Bulgaria herb outdoors 37.77 9,488
2017 Central African Republic herb outdoors 130.00 60.00 55 10.00  250,000 22
2016 Chile herb indoors 26,988 2,740
2016 Chile herb outdoors 58,950 264
2017 Chile herb indoors 50,414 2,408
2017 Chile herb outdoors 194,694 202
2018 Chile herb indoors 66,007 2,357
2018 Chile herb outdoors 183,185 318
2019 Chile herb indoors 31,711 1,856
2019 Chile herb outdoors 199,523 212
2016 China herb outdoors 9.80 1,390,000
2018 China herb outdoors 710




























2019 China, Hong Kong SAR herb indoors  1,693 
2016 Colombia herb outdoors 135.00
2017 Colombia herb outdoors 173.71
2018 Colombia herb outdoors 59.66
2019 Colombia herb outdoors 39.34
2016 Costa Rica herb indoors 678.00 5
2016 Costa Rica herb outdoors 17.59 2,122,244 201
2017 Costa Rica herb indoors 2
2017 Costa Rica herb outdoors 14.30 215
2018 Costa Rica herb indoors 4
2018 Costa Rica herb outdoors 11.41 11.41 1,346,273 208
2019 Costa Rica herb indoors 2
2019 Costa Rica herb outdoors 11.56 11.56 1,419,495 224
2016 Côte d’Ivoire herb outdoors 5
2017 Côte d’Ivoire herb outdoors 0.25 1
2018 Côte d’Ivoire herb outdoors 104 1
2019 Côte d’Ivoire herb outdoors 4,848
2016 Czechia herb indoors 53,549 229
2016 Czechia herb outdoors 4,111
2017 Czechia herb indoors 50,925 305
2017 Czechia herb outdoors 3,467
2018 Czechia herb outdoors 6,581
2019 Czechia herb indoors 26,925 258
2019 Czechia herb outdoors 5,526
2015 Denmark herb indoors/outdoors 14,560 97
2016 Denmark herb indoors/outdoors 13,217 105
2018 Denmark herb indoors/outdoors 14,171 99
2019 Denmark herb indoors/outdoors 14,338 79
2014 Dominican Republic herb outdoors 6.00 a 6.00 0.00 0.21 111 8
2017 Denmark herb indoors/outdoors 34,801 65
2016 Ecuador herb outdoors 224 34
2017 Ecuador herb outdoors 397 10
2018 Ecuador herb indoors 127 30
2018 Ecuador herb outdoors 13,891 4
2015 Egypt herb/resin outdoors 140.00
2017 Egypt herb/resin outdoors 126.00
2016 El Salvador herb outdoors 1.00 227 25
2019 Estonia herb indoors 979 27
2019 Estonia herb outdoors 66 2
2018 Eswatini herb outdoors 1,500.00 1,069.50 430.50 3,000,000 210
2018 France herb outdoors 138,561
2014 France herb outdoors 158,592 837
2017 Georgia herb indoors 0.01 186 91
2017 Georgia herb outdoors 0.02 a 0.02 0.00 93 19
2017 Georgia herb indoors 0.01 186 91
2017 Georgia herb outdoors 0.02 0.02 0.00 93 19
2018 Georgia herb indoors 0.05 927 443
2018 Georgia herb outdoors 0.10 0.10 0.00 406 98
2015 Germany herb indoors 135,925 786
2015 Germany herb outdoors  9,136 127































2016 Germany herb outdoors  18,414 108
2017 Germany herb indoors 85,226 573
2017 Germany herb outdoors 95
2016 Greece herb indoors  16,554 
2016 Greece herb oudoors  39,151 
2017 Greece herb indoors  19,498 
2017 Greece herb oudoors  27,409 
2018 Greece herb indoors  6,913 
2018 Greece herb oudoors  43,684 
2016 Guatemala herb outdoors 9.00  3,138,298 427
2017 Guatemala herb outdoors 3.50 a 3.81 1.61  6,033,345 150
2018 Guatemala herb outdoors 129.00 a 129.00 0.00  5,189,422 368
2019 Guatemala herb outdoors 150.00 a 84.26 65.74  3,447,979 127
2015 Guyana herb outdoors 20.00 9.40 10.60 1,000.00  419,700 19
2016 Honduras herb indoors  7 2
2016 Honduras herb oudoors  24,253 19
2017 Honduras herb oudoors 59.58 a 59.59 0.00
2018 Honduras herb oudoors  720,426 67
2019 Honduras herb oudoors  228,542 46
2016 Hungary herb indoors 5,000 3
2016 Hungary herb outdoors 2,000 20
2013 Iceland herb indoors 6,652 323
2016 India herb outdoors 3,414.74
2017 India herb outdoors 3,445.90 6,687,376
2018 India herb outdoors 3,430.12
2019 India herb outdoors 9,023.27
2016 Indonesia herb outdoors 482.00 a 482.00 0.00
2017 Indonesia herb outdoors 89.00 a 89.00 0.00 738,020 14
2018 Indonesia herb outdoors 76.23 a 76.23 0.00 1,455,390 13
2019 Indonesia herb outdoors 103.20 a 84.50 18.70 169.00 845,000 25
2018 Iran (Islamic Republic of) herb indoors 0.04
2016 Ireland herb indoors 7,273
2017 Ireland herb indoors 9,046 50
2018 Ireland herb indoors 7,186
2019 Ireland herb indoors 8,576
2014 Italy herb indoors 51,534 639
2014 Italy herb outdoors 70,125 1,134
2017 Italy herb indoors 56,125 1,161
2017 Italy herb outdoors 209,510 401
2019 Italy herb indoors 68,266
2019 Italy herb outdoors 155,275
2016 Kazakhstan herb outdoors 18.00 a 18.00 0.00 170,000 202
2017 Kazakhstan herb outdoors 12.30 a 12.30 0.00 930,774 91
2016 Kenya herb outdoors 12.00 8,747 46
2017 Kenya herb outdoors 0.10 4,662
2018 Kenya herb outdoors 0.10 517
2019 Kenya herb outdoors 0.25 a 0.25 0.00 130 1
2015 Kyrgyzstan herb outdoors 5,014.00 5,014.00
2018 Kyrgyzstan herb outdoors 1,276.37 457.69 818.68 49,942 12.00
2016 Latvia herb indoors 557 35




























2017 Latvia herb indoors 798 34
2017 Latvia herb outdoors 66 15
2018 Latvia herb indoors 152 17
2018 Latvia herb outdoors 1,152 34
2019 Latvia herb indoors 932 34
2019 Latvia herb outdoors 61 12
2015 Lebanon herb outdoors 3,500.00 3,500.00
2017 Lebanon Kif outdoors 40,772.00
2018 Lebanon herb outdoors 4,205.70 4,205.70
2016 Lithuania herb indoors 4
2017 Lithuania herb indoors 8
2017 Lithuania herb outdoors 7
2018 Lithuania herb indoors 3
2015 Madagascar herb outdoors 11.00 21,325
2017 Madagascar herb outdoors 9.00 57,708
2013 Malta herb indoors 27
2016 Mexico herb outdoors 5,478.42 6,574.1 38,432
2017 Mexico herb outdoors 4,193.34 5,032.0 34,523
2018 Mexico herb outdoors 2,263.71 2,726.47 28,873
2013 Mongolia herb outdoors 15,000.00 4,000.00 11,000.00 4,000 4,000
2018 Mongolia herb outdoors 15,000.00 173.00 14,827.00 33
2016 Morocco herb outdoors 35,652.83
2016 Morocco plant outdoors 47,000.00 395.00 46,605.00
2016 Morocco resin outdoors 713.00
2017 Morocco herb outdoors 35,702.90
2017 Morocco plant outdoors 47,500.00 523.00 46,977.00
2017 Morocco resin outdoors 714.06
2018 Morocco herb outdoors 23,699.80
2018 Morocco plant outdoors 47,500.00 47,500.00
2018 Morocco resin outdoors 423.58
2019 Morocco plant outdoors 21,048.71 135.50 20,913.21
2019 Morocco resin outdoors 596.03
2014 Myanmar herb outdoors 15.00 10.00 5.00 3
2018 Nepal herb outdoors 235.87 235.87 0.00 5,000.00 2,358,700 335
2016 Netherlands herb indoors 994,068 5,856
2017 Netherlands herb indoors 883,163 5,538
2018 Netherlands herb indoors 516,418 3,482
2018 Netherlands herb outdoors 431
2019 Netherlands herb indoors 556,802 3,285
2019 Netherlands herb outdoors 350
2016 New Zealand herb indoors 18,903 607
2016 New Zealand herb outdoors 104,725
2017 New Zealand herb indoors 19,992
2017 New Zealand herb outdoors 19,559
2018 New Zealand herb indoors 19,313
2018 New Zealand herb outdoors 22,660
2019 New Zealand herb indoors 18,052
2019 New Zealand herb outdoors 15,269
2014 Nicaragua herb outdoors 0.30 1,507.00 3,014 30
2016 Nicaragua herb outdoors 275,000































2016 Nigeria herb outdoors 718.78 65
2017 Nigeria herb outdoors 317.12
2018 Nigeria herb outdoors 3,660.64
2017 North Macedonia herb indoors 168
2017 North Macedonia herb outdoors 220
2018 North Macedonia herb outdoors 2.51 0.00404 2,264 4,527
2015 Norway herb indoors 0.04 4,000 30
2016 Oman herb outdoors 0.50 a 0.50 0.00 5 3
2013 Panama herb indoors 0.50 a 0.50 0.00 37 2
2013 Panama herb outdoors 10.50 a 10.50 0.00 78,633 2
2016 Paraguay herb outdoors 1,298.50
2016 Paraguay plant outdoors 1,298.50 a 1,298.50 0.00 5,656,266 4
2016 Paraguay resin outdoors 1.15
2017 Paraguay plant outdoors 1,462.00 36,550,000
2016 Peru herb outdoors 87.83 1,429,749
2017 Peru herb outdoors 61.30 4,671,387 47
2018 Peru herb outdoors 91.80 1,716,751 46
2016 Philippines herb outdoors 8.67 24,635,153 337
2017 Philippines herb outdoors 4.82 221,035 27
2018 Philippines herb outdoors 12.39 869,682 186
2019 Philippines herb outdoors 149.35 2,345,650 137
2016 Poland herb indoors 146,755 1,403
2016 Poland herb indoors/outdoors 4,585 219
2017 Poland herb indoors 448 10
2017 Poland herb indoors/outdoors 54
2018 Poland herb indoors/outdoors 118,382 1,274.00
2019 Poland herb indoors 2,840 2
2019 Poland herb indoors/outdoors 5,124 17
2017 Portugal herb indoors/outdoors 22,910 158
2018 Portugal herb indoors/outdoors 8,706 139
2019 Portugal herb indoors/outdoors 12,077 131
2013 Republic of Korea herb outdoors 8,072
2014 Republic of Moldova herb indoors 41.00
2014 Republic of Moldova herb outdoors  100.00 59.00 41.00 10,000.00 200,548
2017 Republic of Moldova herb outdoors  0.15 2.57 257,236
2018 Republic of Moldova herb outdoors 0.71 86,926 61
2019 Republic of Moldova herb outdoors 143,537
2016 Romania herb indoors 1,433 41
2016 Romania herb outdoors 6.99 42
2017 Romania herb indoors 1,875 46
2017 Romania herb outdoors 1.90 4,905 32
2018 Romania herb indoors 3,903 39
2018 Romania herb outdoors 0.11 1,882 98
2019 Romania herb indoors 0.49 2,096 39
2019 Romania herb outdoors 787 44
2016 Russian Federation herb indoors 0.66 788
2016 Russian Federation herb outdoors 7.61 a 7.61 0.00 68.64 1,143
2017 Russian Federation herb indoors 0.87 1,990
2017 Russian Federation herb outdoors 159.00 a 159.00 0.00 30.07 5,379
2018 Russian Federation herb indoors 1.87




























2019 Russian Federation herb indoors 0.72 2,112
2019 Russian Federation herb outdoors 161.10 3,571
2015 Serbia herb outdoors 0.05
2013 Sierra Leone herb outdoors 190.00 190.00 190 3
2016 Slovakia herb indoors 385
2017 Slovakia herb outdoors 2.00 a 2.00 0.00 2,299 31
2019 Slovakia herb indoors 1,611 41
2014 Slovenia herb indoors 9,223 118
2014 Slovenia herb outdoors 1,844
2017 Slovenia herb indoors 10,259 78
2015 Spain herb indoors 244,772 108
2015 Spain herb outdoors 135,074 44
2014 Sudan herb outdoors 8.00 a 8.00 0.00 345.00
2017 Sudan herb outdoors 1,250.00 a 1,250.00 0.00 205.00 100
2018 Sudan herb outdoors 7,744.00 a 1,452.00 6,292.00 774,400.00 1,500,000 3
2014 Sweden herb indoors 10,000 56
2015 Sweden herb outdoors 182.00
2017 Sweden herb indoors 5,100 44
2018 Sweden herb indoors 1,642
2016 Switzerland herb indoors 11,386 83
2017 Switzerland herb indoors 71,750
2016 Thailand herb outdoors 1.00 a 1.00 0.00 7.50 1
2019 Thailand herb outdoors 1.50 a 1.50 0.00 45.00 4,790 53
2019 Togo herb outdoors 0.06 1
2015 Trinidad and Tobago herb outdoors 0.31 375,925 58
2016 Ukraine herb outdoors 91.00 a 91.00 0.00
2017 Ukraine herb outdoors 166.90 483,000
2019 Ukraine herb outdoors 47.00 1,800,000 2,135
2016 United States of America herb indoors 406,125 1,865
2016 United States of America herb outdoors 4,940,596 5,513
2017 United States of America herb indoors 303,654 1,399
2017 United States of America herb outdoors 3,078,418 4,062
2018 United States of America herb indoors 596,149 1,618
2018 United States of America herb outdoors 2,221,837 3,847
2019 United States of America herb indoors 770,472 1,437
2019 United States of America herb outdoors 3,232,722 3,850
2016 Uruguay herb indoors 661
2017 Uruguay herb indoors 1,926
2019 Uruguay herb indoors 1,654
2016 Uzbekistan herb outdoors 0.20 a 0.20 0.00 586
2017 Uzbekistan herb outdoors 0.20 a 0.20 0.00 618
2018 Uzbekistan herb indoors 0.13 a 0.13 0.00 519
2019 Uzbekistan herb outdoors 0.11 a 0.11 0.00 417
2018 Venezuela herb oudoors 13,891 4
2015 Viet Nam herb oudoors 1.00
Sources: United Nations Office on Drugs and Crime annual report questionnaire, government reports and and international narcotics control strategy reports of the United States of 
America.


















opiates — a subset of opioids comprising the various prod-
ucts derived from the opium poppy plant, including 
opium, morphine and heroin.
opioids — a generic term that refers both to opiates and 
their synthetic analogues (mainly prescription or pharma-
ceutical opioids) and compounds synthesized in the body.
problem drug users — people who engage in the high-risk 
consumption of drugs. For example, people who inject 
drugs, people who use drugs on a daily basis and/or 
people diagnosed with drug use disorders (harmful use 
or drug dependence), based on clinical criteria as con-
tained in the Diagnostic and Statistical Manual of Mental 
Disorders (fifth edition) of the American Psychiatric Asso-
ciation, or the International Classification of Diseases and 
Related Health Problems (tenth revision) of WHO. 
people who suffer from drug use disorders/people with drug 
use disorders — a subset of people who use drugs. Harm-
ful use of substances and dependence are features of 
drug use disorders. People with drug use disorders need 
treatment, health and social care and rehabilitation.
harmful use of substances — defined in the International 
Statistical Classification of Diseases and Related Health 
Problems (tenth revision) as a pattern of use that causes 
damage to physical or mental health.
dependence — defined in the International Statistical Clas-
sification of Diseases and Related Health Problems (tenth 
revision) as a cluster of physiological, behavioural and 
cognitive phenomena that develop after repeated sub-
stance use and that typically include a strong desire to 
take the drug, difficulties in controlling its use, persisting 
in its use despite harmful consequences, a higher priority 
given to drug use than to other activities and obligations, 
increased tolerance, and sometimes a physical withdrawal 
state.
amphetamine-type stimulants — a group of substances 
composed of synthetic stimulants controlled under the 
Convention on Psychotropic Substances of 1971 and from 
the group of substances called amphetamines, which 
includes amphetamine, methamphetamine, meth-
cathinone and the “ecstasy”-group substances (3,4-me- 
thylenedioxymethamphetamine (MDMA) and its 
analogues).
amphetamines — a group of amphetamine-type stimulants 
that includes amphetamine and methamphetamine.
annual prevalence — the total number of people of a given 
age range who have used a given drug at least once in 
the past year, divided by the number of people of the 
given age range, and expressed as a percentage.
coca paste (or coca base) — an extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride).
“crack” cocaine — cocaine base obtained from cocaine 
hydrochloride through conversion processes to make it 
suitable for smoking.
cocaine salt — cocaine hydrochloride.
drug use — use of controlled psychoactive substances for 
non-medical and non-scientific purposes, unless other-
wise specified.
fentanyls — fentanyl and its analogues.
new psychoactive substances — substances of abuse, either 
in a pure form or a preparation, that are not controlled 
under the Single Convention on Narcotic Drugs of 1961 
or the 1971 Convention, but that may pose a public health 
threat. In this context, the term “new” does not neces-









substance or drug use disorders — referred to in the Diag-
nostic and Statistical Manual of Mental Disorders (fifth 
edition) as patterns of symptoms resulting from the 
repeated use of a substance despite experiencing prob-
lems or impairment in daily life as a result of using 
substances. Depending on the number of symptoms iden-
tified, substance use disorder may be mild, moderate or 
severe.
prevention of drug use and treatment of drug use disorders 
— the aim of “prevention of drug use” is to prevent or 
delay the initiation of drug use, as well as the transition 
to drug use disorders. Once a person develops a drug use 

















The World Drug Report uses a number of regional and 
subregional designations. These are not official designa-
tions, and are defined as follows:
AFRICA
 > East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, South Sudan, Uganda, United 
Republic of Tanzania and Mayotte
 > North Africa: Algeria, Egypt, Libya, Morocco, Sudan 
and Tunisia
 > Southern Africa: Angola, Botswana, Eswatini,  
Lesotho, Malawi, Mozambique, Namibia, South 
Africa,  Zambia, Zimbabwe and Reunion
 > West and Central Africa: Benin, Burkina Faso,  
Cabo Verde, Cameroon, Central African Republic, 
Chad, Congo, Côte d’Ivoire, Democratic Republic of 
the Congo, Equatorial Guinea, Gabon, Gambia, 
Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauri-
tania, Niger, Nigeria, Sao Tome and Principe, Senegal, 
Sierra Leone, Togo and Saint Helena
AMERICAS
 > Caribbean: Antigua and Barbuda, Bahamas,  
Barbados, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines, Trinidad and 
Tobago, Anguilla, Aruba, Bonaire, Netherlands, 
British Virgin Islands, Cayman Islands, Curaçao, 
Guadeloupe, Martinique, Montserrat, Puerto Rico, 
Saba, Netherlands, Sint Eustatius, Netherlands, Sint 
Maarten, Turks and Caicos Islands and United States 
Virgin Islands
 > Central America: Belize, Costa Rica, El Salvador, 
Guatemala, Honduras, Nicaragua and Panama
 > North America: Canada, Mexico, United States of 
America, Bermuda, Greenland and Saint-Pierre and 
Miquelon 
 > South America: Argentina, Bolivia (Plurinational 
State of), Brazil, Chile, Colombia, Ecuador, Guyana, 
Paraguay, Peru, Suriname, Uruguay, Venezuela 
(Bolivarian Republic of) and Falkland Islands 
(Malvinas)
ASIA
 > Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan,  
Turkmenistan and Uzbekistan
 > East and South-East Asia: Brunei Darussalam, 
Cambodia, China, Democratic People’s Republic of 
Korea, Indonesia, Japan, Lao People’s Democratic 
Republic, Malaysia, Mongolia, Myanmar, Philippines, 
Republic of Korea, Singapore, Thailand, Timor-Leste, 
Viet Nam, Hong Kong, China, Macao, China, and 
Taiwan Province of China
 > South-West Asia: Afghanistan, Iran (Islamic Republic 
of) and Pakistan 
 > Near and Middle East: Bahrain, Iraq, Israel, Jordan, 
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syrian 
Arab Republic, United Arab Emirates, Yemen and 
State of Palestine
 > South Asia: Bangladesh, Bhutan, India, Maldives, 
Nepal and Sri Lanka 
EUROPE
 > Eastern Europe: Belarus, Republic of Moldova, 
Russian Federation and Ukraine
 > South-Eastern Europe: Albania, Bosnia and  
Herzegovina, Bulgaria, Croatia, Montenegro,  
North Macedonia, Romania, Serbia, Turkey and 
Kosovo1
1 References to Kosovo shall be understood to be in the context of 






















 > Western and Central Europe: Andorra, Austria, 
Belgium, Cyprus, Czechia, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Iceland, Ireland, 
Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, 
Malta, Monaco, Netherlands, Norway, Poland, 
Portugal, San Marino, Slovakia, Slovenia, Spain, 
Sweden, Switzerland, United Kingdom of Great 
Britain and Northern Ireland, Holy See, Faroe Islands 
and Gibraltar 
OCEANIA
 > Australia and New Zealand: Australia and  
New Zealand
 > Polynesia: Cook Islands, Niue, Samoa, Tonga, Tuvalu, 
French Polynesia, Tokelau and Wallis and Futuna 
Islands
 > Melanesia: Fiji, Papua New Guinea, Solomon Islands, 
Vanuatu and New Caledonia
 > Micronesia: Kiribati, Marshall Islands, Micronesia 

















Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth 
analysis of the global drug markets and paints a comprehensive picture of the measurable 
effects and potential impact of the COVID-19 crisis on the world drug problem. 
Booklet 1 summarizes the four subsequent booklets by reviewing their key findings and 
highlighting their policy implications. Booklet 2 offers a projection of the impact of popu-
lation growth on drug use by 2030 and gives a global overview of the supply of and demand 
for drugs, including their health impact and the trafficking of substances over the Internet. 
Booklet 3 provides an analysis of the global markets for cannabis and opioids, both in terms 
of supply and use, and includes an overview of the latest developments in countries with 
measures regulating the non-medical use of cannabis; it also discusses the overlaps between 
the various opioids and looks at access to pharmaceutical opioids for medical use. Booklet 
4 contains the latest trends in and estimates of the markets for stimulants – cocaine, meth-
amphetamine, amphetamine and “ecstasy” – both at the global level and in the most affected 
subregions. Booklet 5 presents an early assessment of the impact of the COVID-19 pandemic 
on drug markets by looking at how it has affected drug supply and demand dynamics, 
including in terms of health consequences and how drug service provision has adapted to 
the new situation in many countries; the booklet closes with a look at how the pandemic 
may influence long-term changes in the drug markets.
The World Drug Report 2021 is aimed not only at fostering greater international cooperation 
to counter the impact of the world drug problem on health, governance and security, but 
also, with its special focus on the impact of the COVID-19 pandemic, at assisting Member 
States in anticipating and addressing challenges that may arise in the near future.
The accompanying statistical annex is published on the UNODC website:  
www.unodc.org/unodc/en/data-and-analysis/wdr2021.html
Vienna International Centre, PO Box 500, 1400 Vienna, Austria
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